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ABSTRACT 
 
Boron neutron capture therapy (BNCT) is a method for selectively destroying malignant 
(normally glioma) cells whilst sparing normal tissue. Irradiation of 
10
B (large neutron 
capture cross-section) with thermal neutrons effects the nuclear fission reaction: 
10
B + 
1n → 
→ 7Li+ +  + ; where the penetration of -particles and 7Li+ is only 8 and 5 µm, 
respectively, i.e., within a single cell thickness, assuming 
10
B can be preferentially located 
within glioma cells. Poor selectivity is the main reason why BNCT has not become a 
mainstream cancer therapy. Carboranes. a third generation of high boron-containing, low-
toxicity,  BNCT compounds, are currently being investigated. 
 
Towards the aim of increasing malignant cell targeting specificity, this thesis investigates 
monodispersed dipalmitoylphosphatidylcholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) SUV liposome formulations containing carboranes derivatised with 
delocalised lipophilic cations (DLCs), specifically the dequalinium bis nido carborane salt. 
AFM studies showed the loaded liposomes appeared stable (63 days, 4°C, if re-probing was 
employed). The integrity of the liposome membrane in serum, as reflected by %latency and 
%retention experiments using a fluorescent marker (calcein), was found to be high for both 
types of liposomes prepared using cholesterol. Successful entrapment of carboranes was 
demonstrated by the Nile Red method and by ICP-MS measurements. The liposomes were 
of sufficient size (80-100 nm) to pass through the blood brain barrier (BBB). The cationic 
moiety of the carborane salt allowed selective targeting of glioma mitochondria, thought to 
be due to differences in mitochondrial membrane potentials between malignant and non-
neoplastic cells. Specific targeting of IN699 (glioma, WHO grade IV) and SC1800 (non-
neoplastic astrocyte) cells with the carborane salt was evidenced by live cell (fluorescence) 
imaging.  
 
Spray drying was used as an alternative method of formulating agents for BNCT treatments 
for liver and lung cancers, where the larger (micrometre-diameter) particles do not need to 
pass across the BBB. Polyvinylpyrrolidone / o-carborane co-spray-dried microparticles were 
produced. 
1
H NMR studies revealed the high temperatures (180 °C) of the spray drying 
process did not degrade the PVP. Mean particle diameters (x90) were in the 2 – 10 µm range, 
with finer fractions being present (x10  1 – 2 µm), and were therefore considered suitable 
for delivery to the lungs. SEM imaging showed the particles to be spherical, with dimples 
and cavities caused by the spray drier nozzle characteristics, as typical with the spray drying 
process. Some small irregularly-shaped crystalline particles, thought to be o-carborane, were 
observed by SEM, although the proportion accounted for less that than in the formulation 
(10 %w/w). An attempt was made to map the boron content in spray-dried powders on a 
surface using EDS, although the low atomic weight of boron made detection not possible. 
Cytotoxicity studies, using human glioblastoma U-87 MG (cancerous) and human fetal lung 
fibroblast MRC-5 (non-neoplastic) cells, revealed the PVP / o-carborane co-spray-dried 
particles to be non-toxic. 
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 vii 
Words of admonitions and encouragements 
 
Ise Ni Ogun Ise 
(Yoruba and English Translations) 
 
Ise ni ogun `se        The antidote to poverty is hard work 
Mura si ise ore mi   So work hard, dear friend 
Ise ni a fi n deni giga   Success only comes through hard work 
Bi a ko ba re ni fehin ti  When there is no one to rely on 
Bi ole la a ri    It’s like we are lazy 
Bi a ko ba reni gbekele  When there is no one to trust 
A te ra mo se eni   We focus on our work 
Iya re le lowo lowo   Your mother may be rich 
Baba re si le leshin le kan  Your father may own a thousand and one horses 
Bi o ba gboju le won   If you rely on their wealth 
O te tan ni mo so fun o  You are sinking fast to your shame. 
Ohun ti a ko ba jiya fun  Whatever we do not work for 
Se kii le tojo    Will not last 
Ohun ti a ba fara sise fun  It is what we strive for 
Ni npe lowo eni   That last 
Apa lara, Igunpa ni iye kan  Your arms and elbows are your instruments of work 
Bi aiye ba nfe o loni   If you are feted by society today 
Ti o balowo lowo   If you are still rich,  
Won a ma fe o lola   They will fete you tomorrow as well. 
Jeki o wa ni ipo atata   When you hold an esteemed position 
Aiye a ma ye o si terin-terin  You will be regarded with great joy 
Jeki o deni ti n rago   Just wait and become a pauper and  
Ko o ri bi aiye ti nyinmu si o  And see how you will be treated with disdain 
Eko si tun so ni doga   Education can take you to the top 
Mura ki o ko dara-dara  So study hard  
Iya nbo fomo ti ko gbon  The unwise will surely regret their folly 
Ekun mbe fomo ti o nsa kiri  The result for lack of planning is tears 
Ma fowuro sere ore mi  Don’t waste your early years 
Mura si ise ojo n lo!                  Make hay while the sun shines. 
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CANCER 
“The Enemy WITHIN” 
 
 
 
Standing in the mist of Unknown, 
I look around to see the unseen, 
Oh! What a waste of time untold, 
Searching for the enemy within. 
 
Standing in the midst of unknown, 
Science told me the enemy is within, 
Growing gradually unknown, 
In those whose temple unscreened! 
 
Standing in the mist of unknown, 
The battle begins unfold, 
The enemy within untold, 
That the battle against it is on course, 
Soon to be won in all 
         Whose temple are screened and scanned! 
 
Standing in the midst I know, 
That the battles against it are told, 
By the comrades of science we know, 
That cancer, the enemy within, 
Will soon be cancelled assured! 
 
T.O.B Olusanya 
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Introduction 
1.1 Cancer 
Cancer is the name given to abnormal growth of cells in the body system initiated by 
genetic mutations in proto-oncogenes, tumour suppressor genes or DNA repair genes [1]. 
The first investigations of cancer were reported in 1600 BC in Egypt, where Papyrus 
discovered various cancers and the use of natural products for their treatment [2]. 
 
In the UK, one third of people will develop one form of cancer in their lifetime [3]. The 
diagnosis rate in males between 25 and 35 years of age is over a 10 000 cases in 100 000 
people; the rate for females in over 2 000 cases for the same population. The survival rate 
of a certain cancer, which depends on the type of neoplastic tissue, is described as the 
patient survival after 5 years since diagnosis [4]. The occurrence of malignant tumours is 
higher than benign tumours [5]. 
 
The origin of cancer starts from a cell that has undergone genetic mutation [6,7]. The 
elucidation of cancer depends on knowing when a normal cell becomes cancerous [8]. The 
body is made up of many types of cells, which are the basic units of life [9]. For a healthy 
body living, cells grow and multiply to produce more daughter cells. However, when 
critical cell damage occurs, cell take another route to obliterate the damage through a 
pathway that results in apoptosis (cell suicide) for the replacement of old cells (cell 
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senescence) (Figure 1.1) [10,11]. This programmed cell death (apoptosis) is guarded by 
signalling pathways. 
 
 
Figure 1.1. The origin of cancer: uncontrolled cell growth. 
 
There are many factors that contribute to the onset of cancer, which may be grouped under 
the terms physical (environmental hazards, smoking, diet, UV exposure), chemical 
(occupational hazards, nitrosamines, asbestos) and biological (viruses, bacteria) 
carcinogenesis. These activate the method that leads to the deregulation of genes for 
proliferation of neoplastic tissues [12]. Different types of cancer are dominant in different 
parts of the world [13]. For example, in Japan, stomach cancer is well known; in the US, 
colon is prominent; skin cancer is a major type in Australia, caused by excessive exposure 
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to sunlight, which can lead to melanoma [14]. The high incidences of one type of cancer 
over another are related to different hereditary factors (genetic) and 
geographical/environment location [15]. Tobacco smoking causes more danger to health 
because it contains more than 24 chemicals that are liable to cause cancer, especially to the 
lung, mouth, larynx, oesophagus, stomach, pancreas, kidney and bladder. 
 
Tumour protein P53, described as ‘the guardian of the genome’ (named after its function), 
is coded by TP53 in humans and triggers cell suicide. It is found on the short arm of 
chromosome 17 and codes for a protein that prompts apoptosis (cell death) that is 
imperative in tumourigenesis [16]. In half of all cancers, mutation in p53 can be observed 
[17]. 
 
1.1.1 Characterisation of tumours 
Tumours can be categorised as either liquid or solid. Leukaemia (cancer of bone marrow 
and blood) and lymphomas are examples of liquid tumours, where the neoplastic cells 
precursors are usually mobile. Solid tumours present the key cancer burden with cancer 
starting in tissues including breast, lung, colon, prostate and ovary constituting ca. 80% of 
all malignant neoplasms [18]. Solid tumours consist of epithelial or mesenchymal cells that 
are usually stationary (immobile). Only one or two mutation are needed to cause a 
malignant liquid tumour [19] and they do not require as much of the pathway to be 
stimulated because their precursors cells are in the mobile phase and are invasive. Solid 
tumours require a minimum of 3 mutations to cause a malignancy in adults and each of the 
mutation causes one alteration or another to their pathways. Chromosome translocations 
are not common in solid tumours [1].  
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Necrosis occurs among collections of cells, visualised under microscope as a zone of 
impaired cells where the release of the inflammatory mediators cause infection or lysis 
within the system. Apoptosis takes place during tissue remodelling [20-22] and 
necroptosis, paroptosis and autophagy are various cell-type dependent methods routes for 
apoptosis [23]. 
 
Not all tumours are cancerous and some cancers, such as leukaemia, do not form tumours 
[24]. Tumour categorisation depends on morphological and histopathological forms of the 
tumour [25]. Tumour cells can be categorised as either benign or malignant [26]. Benign 
tumours are non-cancerous (suffix –oma), are generally not life-threatening and do not 
have the ability to spread (invade or metastatise) to non-affected cellular areas and grow 
locally very slowly. They can be removed surgically by a procedure known as debulking 
[27], which is a very good solution due to the well-defined boundary of limitation. 
Malignant (cancer) tumours cells are morbidly debilitating and invade neighbouring 
tissues, enter blood vessels and metastasize to different sites in the body that make them 
spread sporadically and become cancerous [28]. Malignant melanoma is an aggressive 
neoplasm that is connected with great risk of death [29]. 
 
The malignancy sequence is based on the capacity of a cell to affect other neighbouring 
cells due to activation of matrix metalloproteinase enzymes (MMPs) and angiogenesis [30-
32]. The advancement of neoplasm leads to metastasis which in turns causes the porosity 
deformation of neoplastic cells enhancing tissue leakages (intravasation) [33].  This causes 
a great change in proliferation, morphological assessment of the cell and tissues structural 
design. In a normal cell, the tissue does not need any supply of oxygen from vascularised 
tissues. 
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Tumours can be grouped into Grades 1 to 4, the higher end being the more aggressive and 
unsafe [34-37]. The grades are used to understand patient’s health status and prognosis. 
Staging is another method used in tumour classification; it provides a measure of the extent 
of metastasis. For central nervous system (CNS) tumours, staging is assessed by the results 
from CT or MRI scans, or by cerebrospinal fluid examination [38]. 
 
Cancers spread over the body in two ways: invasion and metastasis [39,40]. The former is 
a straight migration of cancer cells into neighbouring tissues while metastasis is the 
enablement of cancer cells to spread into blood vessels and lymphatic tissues, move around 
the blood stream and invade normal cells elsewhere [41,42]. 
 
Angiogenesis is the growth of new blood vessels [43]. Directly or indirectly, this process 
involves the vascular endothelia growth factor (VEGF), vascular permeability factor (VPF) 
or vasculotropin [44,45]. Migration, genetic signalling and multiplication of endothelial 
cells (ECs) are activated by VEGF and also ECs hyper-permeability in order for plasma 
protein to get into extravascular regions. 
  
A normal cell can become cancerous through a series of morphological alterations and 
synthesis of cell type-specific proteins, but mostly through mutational modification. The 
capability of a cell to have unlimited division is known as immortalisation and is one of the 
main prerequisites of tumourigenesis, carcinogenesis or oncogenesis [46]. A single gene is 
not solely responsible for oncogenesis [47]: a transformation in 3 types of genes - 
oncogenes, tumour-suppressor genes and stability genes - leads to the development of 
cancer [24]. Therefore, cancer could be described as a genetic disease that has undergone 
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abnormal cell division without control, developed from different unfavourable conditions, 
e.g., heredity, menstrual irregularities or physical state [48]. 
 
Cancer is not just one disease but a group of heterogeneous diseases of different malignant 
neoplastic growths. There are more than 100 cancers that have a common hallmark of 
unchecked growth that advances without limitation [7,49,50]. Hallmarks of cancer involve 
six biological abilities: proliferative signalling, evading growth suppression, resistance to 
cell death, enablement of replicative immortality, inducement of angiogenesis and 
activation of invasion and metastasis [50]. 
 
Cancer can form in any part of the body, although the name of any particular cancer 
indicates where it originated. A primary cancer indicates the site of the cancer is where it 
originated, whereas a secondary cancer denotes one that has metastasised or infiltrated to 
form a tumour elsewhere in the body [51]. A typical example is colon cancer (primary) that 
spreads to the liver (secondary cancer): this is then called metastatic colon cancer and 
cancer that begins in melanocytes of the skin is melanoma (primary cancer). A brain 
tumour might be primary or secondary: if it starts from the brain, it is primary (benign or 
malignant), but if the cancer metastasises to the brain from other organs, such as from skin, 
eye, colon, breast etc, then the cancer is denoted a secondary brain cancer [52]. 
 
In only a very low percentage of cases are patients having a secondary tumour in which the 
origin (primary site) is not known, i.e., cancer of unknown primary origin (CUP) [53-55]. 
CUP is a set of heterogeneous neoplasms that share unique clinical features, but without a 
specific site of origin at the time of diagnoses [56]. This may be because the primary 
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tumour is too small to be detected by imaging tests and/or is cleared away before the 
secondary tumour begins; there may also be many primary sites. CUP can appear 
anywhere, but are mostly found in the lymph nodes, liver, lungs, bones or skin.  
 
1.1.2 Naming cancers 
Various methods have developed for naming cancer to differentiate them from one another, 
e.g., carcinomas, sarcomas, lymphomas and leukaemia (Table 1.1). Latin prefixes are used 
to indicate the location of the primary (Table 1.2). For instance, the prefix “osteo” means 
bone, i.e., cancer that originates in bone is osteosarcoma, while “adneo” means gland: 
adenocarcinoma. 
 
Table 1.1. Main categories of cancer. 
Category Origin 
Carcinoma Skin or in tissues that cover internal and external organs. 
Different types: adenocarcinoma, basal cell carcinoma, 
squamous cell carcinoma and transitional cell carcinoma. 
Sarcoma Bone, cartilage, fat, muscle, blood vessels or other 
connective or supportive tissue. 
Leukaemia Blood-forming tissue such as the bone marrow. Causes large 
numbers of abnormal blood cells to be produced and enter 
the blood. 
Lymphoma and myeloma Cells of the immune system. 
Central nervous system 
cancers 
Brain tissues and spinal cord. 
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Table 1.2. Cancer prefixes and meanings.  
Prefix Meaning 
Adeno Gland 
Chondro Cartilage 
Erythro Red blood cell 
Hemangio Blood vessels 
Hepato Liver 
Lipo Fat 
Lympho Lymphocyte 
Melano Pigment cell 
Myelo Bone marrow 
Myo Muscle 
Osteo Bone 
 
1.2 Brain tumours 
1.2.1 Brain anatomy  
The brain and the spinal cord form the two parts of the central nervous system (CNS). The 
brain can be divided into three categories: fore-brain (prosencephalon), the mid-brain 
(mesencephalon) and the hind-brain(rhombencephalon) (Figure 1.2; Table 1.3) [57,58]. 
The prosencephalon consists of the diencephalon (cerebral cortex) and telencephalon 
[57,59,60] and it is used for the collection and sensory information processing, thinking, 
perceiving and understanding language and controlling of motor neurons. The 
diencephalon is situated at the posterior region of the forebrain, which also consists of the 
thalamus and hypothalamus [58] that are for controlling motor neurons, relaying sensory 
information and for autonomic purpose. The telencephalon is  the largest part of the brain  
and consists of two main parts: the cerebral hemisphere and the median region (the lamina 
terminalis) [58]. 
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Figure 1.2. Structure of the brain: (a) lateral view, and (b) mid-sagittal sectional view [57]. 
 
The midmain (mesencephalon) [58] is the integral part of the brainstem that joins with the 
hindbrain and the forebrain, i.e., with the pons underneath and  the diencephalon on top 
[57]. The midbrain is for auditory, motor functioning and visual responses. The mid- and 
hindbrain are jointly known as the brainstem. 
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Table 1.3. Brain physiological structures and function [57]. 
Brain structure Function 
Basal Ganglia  Involved in cognition and voluntary movement 
 Diseases related to damages of this area are Parkinson’s 
and Huntington’s 
Brainstem  Relays information between the peripheral nerves and 
spinal cord to the upper parts of the brain  
 Consists of the midbrain, medulla oblongata, and the pons 
Broca’s Area  Speech production 
 Understanding language 
Central Sulcus (Fissure of 
Rolando) 
 Deep grove that separates the parietal and frontal lobes 
Cerebellum  Controls movement coordination 
 Maintains balance and equilibrium 
Cerebral Cortex  Outer portion (1.5 mm to 5 mm) of the cerebrum 
 Receives and processes sensory information 
 Divided into cerebral cortex lobes 
Cerebral Cortex Lobes  Frontal Lobes: involved with decision-making, problem 
solving and planning 
 Occipital Lobes: involved with vision and colour 
recognition 
 Parietal Lobes: receives and processes sensory information 
 Temporal Lobes:  involved with emotional responses, 
memory and speech 
Cerebrum  Largest portion of the brain 
 Consists of folded bulges called ‘gyri’ that create deep 
furrows 
Corpus Callosum  Thick band of fibres that connects the left and right brain 
hemispheres 
Cranial Nerves  Twelve pairs of nerves that originate in the brain, exit the 
skull, and lead to the head, neck and torso 
Substantia Nigra  Helps to control voluntary movement and regulates mood 
Wernicke’s Area  Region of the brain where spoken language is understood 
Medulla Oblongata  Lower part of the brainstem that helps to control 
autonomic functions 
Meninges  Membranes that cover and protect the brain and spinal 
cord 
Olfactory Bulb  Bulb-shaped end of the olfactory lobe 
 Involved in the sense of smell 
Pineal Gland  Endocrine gland involved in biological rhythms 
 Secrets the hormone melatonin 
Pituitary Gland  Endocrine gland involved in homeostasis 
 Regulates other endocrine glands 
Pons  Relays sensory information between the cerebrum and the 
cerebellum 
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The hindbrain (rhombencephalon) runs from the spinal cord and consists of metancephalon 
(pons and cerebellum) and myelencephalon (medulla oblongata) [58]. The pons and 
cerebellum are used to maintain balance equilibrium, for coordination and sensory 
information. The myelencephalon comprises the medulla oblongata that is important for 
controlling breathing, heart rate and digestion. 
 
1.2.2 Brain tumours 
Brain tumours (gliomas) are extremely heterogeneous both morphologically and 
genetically [61], and include various types such as astrocytomas, oligodendrogliomas and 
ependymomas [62]. High grade gliomas, especially glioblastoma multiforme (GBM, a 
grade IV glioma) are highly terminal and resistant to many different modalities of therapy, 
including chemotherapy [63,64]. 
 
The brain consists of neurones (or nerve cells) and glial cells (supporting tissues). The 
former represent the part of the brain that allows it to convey electrical messages to 
different part of the body, whereas the glial tissues allow the passage of blood vessels in 
and out of the brain, which is protected by membranes/lining known as meninges. Primary 
brain tumours may originate from any of these types of cells. Secondary tumours, which 
are more common, originate from other parts of the body, such as lung, skin, prostate and 
breast. 
 
Clinical diagnosis of glioma is usually obtained from histology [65]. Around 5000 cases of 
brain tumours are diagnosed monthly [66]. They are mostly found in the elderly, although 
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do occur across a range of ages [67,68]. Malignant brain tumour proliferation is rapid and 
even when debulking surgery has been performed, micro-invasive infiltration into normal 
cell regions can occur [28]. Brain tumours do not metastasise to other organs and thus are 
primary tumours. Patients with gliomas generally have a very poor prognosis [69]: The 
radio-chemotherapeutic (temozolomide, Section 1.5.3.1) which is the current standard of 
treatment has a 5-year survival of 65% and a 7.5 year median survival [70,71]. Leaving 
behind cancerous tissue due to uncertainties in the surgical margin and multiple cancer 
sites is a major problem with surgery [72-74]. 
 
1.3 Liver cancer 
1.3.1 Structure of the liver 
The liver is a cone-shaped, dark reddish-brown organ located beneath the lower rib cage 
under the diaphragm in the upper right-hand portion of the abdominal cavity. In a healthy 
adult, the liver weighs 1200-1500 kg and the length is about 8 inches long, being larger in 
men than in women. The liver is described as a “workhorse” since the majority of 
metabolic activities are undertaken in this organ [75]. It consists of two main lobes, each 
comprising of many lobules which are connected to small ducts. The left and right lobes 
are anteriorly parted by a peritoneum known as the Falciform ligament (Figure 1.3), with 
these lobes being parted posteriorly by Fissure for ligamentum venosum [76]. There are 
two primary sources of blood supply to the liver: the hepatic artery (oxygenated blood) and 
the hepatic portal vein (deoxygenated blood, venous blood), containing nutrients. 
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Figure 1.3. Anterior (left) and posterior view (right) of the liver [76]. 
 
The functions of the liver can be separated into three main areas: metabolism, filtration and 
secretion. In the former, the liver breaks down nutrients, and some drugs, in the blood 
supplied from the spleen, stomach and intestinal tract. After this, the metabolites are either 
transported to other tissues or retained in the liver for future usage, e.g., storage of 
glycogen. As a vascular filter, unwanted materials are removed from the blood to maintain 
homeostasis. The blood vessels in the liver lobes hold ca. 10% of the blood in the body. 
The liver also secretes a product known as bile to help sequester liver waste products and 
also to aid fat digestion. A numbers of diseases can arise from malfunctioning of the liver, 
such as hereditary disorder, drug-induced damage and cancer. 
 
1.3.2 Liver cancer 
Liver cancer is the sixth most common cancer and the third most common of all deaths, 
universally having a poor prognosis [77]. Hepatocellular carcinoma (HCC) is most popular 
malignant neoplasm of the liver [78]. Others include hepatoblastoma in children, 
Cholangio carcinoma in adults and angiosarcoma from blood vessels [77]. 
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Cancer of the liver is a malignant neoplasm syndrome. The diagnosis of liver cancer at late 
stage has a poor prognosis that has become a bottle neck for health practioners [79,80]. 
Cancer stem cells (CSCs) are the basis of the majority of solid tumours [81]. The liver is 
more prone to cancer due to the large number of metabolisms that take place, such as 
xenobiotic, lipid, carbohydrate, amino acid and hormone metabolism, in addition to 
degradation of plasma protein, storage of vitamins and metals [82]. There are many causes 
of liver cancer, e.g., hepatocellular carcinoma (Figure 1.4); one of the major causes is the 
change of homeostasis balance of S-adenosylmethionine (SAMe) synthesis and 
catabolisation in the liver [83]. 
 
 
Figure 1.4. Causes of liver cancer [84]. 
 
1.4 Lung cancer 
1.4.1 Structure of the lungs 
The lungs are used for gas exchange and are both located in a single compartment [85]; 
they are composed of a bronchial tree [86,87] that occupies the majority of the thoracic 
cavity (Figure 1.5). 
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Figure 1.5. Structure of the lung [94].  
 
The lungs are a soft, spongy mesh of tissues, comprising of alveolar cells and elastic 
connective tissues [88]. The lungs are separated from each other by the mediastinum 
[89,90]. Further down the trachea, there is a separation into the left and right primary 
bronchi. These structures are asymmetrically branched [86] into continuously decreasing 
airways (bronchioles) until they terminate in tiny sacs called alveoli [91]. Blood vessels 
enter the lungs at a structure called the hilum. The right lung is made up of three lobes and 
is shorter, wider and of greater volume than the left lung since it grows faster [92] while 
the left lung comprises two lobes, being longer and narrower than the right and having a 
hollow called cardiac notch. Each of the lungs is surrounded by double layered membrane, 
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called the pleural [91]. The visceral pleural is strongly attached to the periphery layer of 
the lung. Through the hilum, the visceral pleural is extended with the parietal pleura that 
covers the wall of the thoracic cavity. The small space between the visceral and the parietal 
pleurae is known as the pleural cavity [91], which has a film of fluid that is produced by 
the pleura. The fluid serves as an emollient to decrease friction and also helps to hold the 
lung layers together as the alveoli inflate and deflate during gas exchange [93]. 
 
1.4.2 Lung cancer 
Data collected by WHO suggest that lung diseases are responsible for 71% of the total 
disease burden worldwide [95]. Lung cancer (small cell carcinoma) causes the largest 
number of cancer deaths in men and women in developed countries and worldwide 
[96,97], accounting about 1/6th of all deaths [98-102]. Lung cancer accounts for 1.35 
million of the overall cases globally and 1.18 million deaths recorded in 2002, while in 
2008, this had increased to 1.6 million reported cases and 1.4 million deaths [102]. Lung 
cancer incident rates in men are more prominent in Southern Europe, North America and 
Eastern Asia. In women, the highest incidence rate are mainly in Northern Europe, 
Australia, North America and New Zealand [102]. The majority of the lung cancers burden 
would be eradicated if only people could do away with cancer-associated life-styles, e.g., 
tobacco products in-take and westernised nutrition [102]. Increasing the price of tobacco, 
having counter-advertisements, prohibiting smoking in public could lead to a reduction in 
the number of incidences of this disease [103]. Annual data collected from WHO predicts 
tobacco consumption is leading to a lung cancer epidemic that will last for several years 
[96,102]; however, recent advances in early detection technology [104,105] and targeted 
therapies show future promise [105]. 
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Lung cancers used to be treated solely using radiotherapy, whereas now, surgery, combined 
surgery-radiotherapy, chemotherapy and intra bronchial arterial infusion have led to slight 
increased survival rates [106,107]. Patients with early stage lung cancer can be treated with 
thoracic surgery (cure rate ≈ 80%). Advanced lung cancers are usually treated with 
combined therapies. 
 
1.5 Cancer therapies 
The best strategy for the treatment of cancer cells is early discovery of cancer which is 
important in the treatment and eradication of cancerous cells; using targeted therapeutic 
agents that stop the advancement of early neoplastic tissue development [108]. In this way 
the problem of malignancy can be overcome before getting to the late-stage because the 
sooner a cancer is detected and treatment begins, the better the chances that the treatment 
will be effective [29,48,108-113]. Cancer therapy focused on inducing cell death of tumour 
cells whilst causing low toxicity or no harm to the normal cells [114]. The best cancer 
therapy effectively attacks the main parameters that cause tumours, the heterogeneity and 
growth capability [111]. Therapeutic interventions include surgery, radiotherapy and 
chemotherapy and combinations thereof. The sections below outline these methods with a 
particular emphasis on brain tumour therapies. 
 
1.5.1 Surgery 
Surgical therapy is invasive and it is the main technique for treatment of the brain tumour 
because of problem of detecting brain tumour at early stage [115]. The only problem in 
surgery is the removal of the tumour without damaging other vital areas (cognitive, motor 
neurons, reflexes etc) in the brain. To confirm the historical type, classification, grade and 
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potential aggressiveness of cancer, an invasive biopsy is often carried out. Surgery is often 
recommended initially for the removal of brain tumours. 
 
1.5.2 Radiotherapy 
Radiation is a non-invasive treatment and is often used immediately after surgery. It is also 
useful for killing tumours at an early stage of their development. Radiation is administered 
in very low dosage (1.8- 2.0 Gray (GY)) and given to patients on a weekly basis to allow 
normal tissues to recover from sub-lethal destruction [116]. Radiation treatment is often a 
slow process and carries the risk of reducing mental reasoning and initiating secondary 
tumours in the area of irradiation [117]. In children, radiation can affect brain development 
[118]. The performance of radiation therapy is mostly prevented by invasive diffusion 
characteristics of the brain tumour coupled with radiation resistance in populations. 
 
1.5.3 Chemotherapy 
Chemotherapeutic agents have a low therapeutic index. Chemotherapy is toxic and can 
affect not only cancer cells but also healthy cells which lead to severe systemic effects and 
all too often to patient deaths [119-121]. Chemotherapy treatment of brain cancer is not 
common due to the BBB that prevents passage of a wide range of potential anticancer 
drugs. 
 
Using more than one drug (combinational chemotherapy) is a widely accepted practice in 
oncology, although multidrug resistance (MDR) by neoplastic cells is common [122]. This 
is due to the drug efflux character of p-glycoprotein or multidrug resistance protein [123]. 
The former is an ATP-dependent transporter in charge of cellular extrusion of many drugs 
and is found in many tissues (e.g., luminal brain of the cerebral endothelium). 
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Administrations of drugs are typically spaced up to three weeks between treatments to 
allow repopulation of injured proliferating cells [116]. During this time, however, 
neoplastic cells can also recover and thus the efficiency of chemotherapy can become 
limited. 
 
1.5.3.1 Brain tumour chemotherapy using temozolomide 
Temozolomide (TMZ; Temodar, Temodal, Temcad; 5-(3-methyltriazen-l-yl) imidazole-4-
carboximide, MTIC; Figure 1.6) is an orally administered drug for the treatment of Grade 
IV gliomas; it has a high oral bioavailability [124-128]. It is also used for malignant 
melanoma (anaplastic astrocytoma) [124]. TMZ works by methylating DNA, usually at N-
7 or O-6 positions of guanine residues [125,127,128]. This initiates the apoptosis process 
of the tumour cells. The drug is not as popular as it once was in the 1970s and 80s [127], 
and research is now being carried out in combining the therapy with chloroquine [129], 
epigallocatechin gallate (EGCG, green tea) and other agents [126-130]. 
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Figure 1.6. Structure of Temozolomide. 
 
1.5.4 Radiochemotherapy 
Radiochemotherapy is combination of radiation and chemical therapy that has been used 
with mixed success in the treatment of adult brain tumours [131]. Both radiotherapy and 
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chemotherapy are administered in multiple doses allowing time for the recovery of normal 
cells between the treatments [116]. A study has shown that temozolomide is the best and a 
generally well-tolerated drug for the treatment of gliomas and its efficacy can be enhanced 
when used in combination with radiotherapy [27]. Median survival times are improved 
from 12.1 to 14.6 months for the addition of temozolomide to radiotherapy treatment [27]. 
 
1.5.5 Proton therapy 
Much recent media interest has been paid to proton therapy. In conventional x-ray 
radiation, the energy from primary photons and secondary electrons are projected as a 
beam that penetrates beyond the cancer site which can adversely affect normal cells [132]. 
Proton therapy is a form of radiotherapy, but a beam of protons is directed towards the 
cancer, causing ionisation and therefore DNA damage to the cancer, but does not penetrate 
beyond the cancer site; the penetration depth can be precisely controlled (Figure 1.7). This 
minimises the damage to normal cells. Clinical use of the technique came into place in the 
1970s and is increasing used around the world [133], particularly for paediatric 
malignancies [134], which has helped in cure rate of most childhood neoplasms offering a 
5 year survival rate of 56 – 75% [135,136]. 
 
1.5.6 Photodynamic therapy 
Photodynamic therapy involves introducing a photosensitiser, such as pholofrin, to the 
tumour and exciting it at the correct wavelength to produce an oxygen radical/some other 
reactive oxygen species that can stimulate apoptosis whilst reducing systemic toxicity 
[137]. The treatment is mainly restricted to cutaneous malignancies and those of the 
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bladder that can be readily reached by light, although is being extended to treatment of 
malignant gliomas [138] with reported increases in median survival [139]. 
 
 
Figure 1.7. The differences in radiation path between proton therapy and standard x-ray 
radiotherapy for the treatment of brain tumours. 
 
1.5.7 Gene therapy 
Gene therapy is a medical technique that offers enormous potential for solving the 
challenges of cancer worldwide by correcting the disease at a biomolecular level. If a 
specific gene can be inserted or a mutant gene ‘switched off’ then the disorder can be 
treated ‘at source’ [140]. The therapeutic aim is to introduce genetic biomaterial into the 
cell that codes for the missing or deficient protein or siRNA/shRNA [141-146]. Gene 
therapy has the capability of withstanding a prolong administration of a single dose. Genes 
are hydrophilic, charged and are large molecules, however, so mechanisms of passing the 
BBB are required. 
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1.6 Boron neutron capture therapy 
1.6.1 Principle of BNCT 
In 1936, Locher proposed a treatment for cancer using neutrons [147] that was later 
extended to the technique known as Boron Neutron Capture Therapy (BNCT) [148-151]. 
This technique is a non-conventional radio-chemotherapy technique [152-156] that 
provides a way of selectively destroying malignant cells and sparing the normal cells 
[28,157]. Boron (
10
B) has a large neutron capture cross-section and when the element is 
irradiated with low-energy (thermal) neutrons, a nuclear fission reaction occurs to yield 
high-linear-energy-transfer (HLET) α-particles (1.5 MeV) and a recoiling 7Li+ (0.8 MeV; 
ca. 2.4 MeV for both fragments) [158-162] (Figure 1.8). The penetration of the α-particles 
and 
7
Li
+
 into surrounding tissues is only 8 and 5 µm, respectively, and so the highly-
ionising energy dose is confined to the original 
10
B containing cell or at least to the 
adjacent cells. Since the collateral damage is very low, this in principle, allows for a 
particularly targeted therapy (Figure 1.9). For this to occur, a sufficient quantity of 
10
B 
must be selectively localised into the cancer cells, and the correct number of thermal 
neutrons must be aimed at the 
10
B-containing cancer cells [163]. 
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Figure 1.8. The BNCT reaction. 
 
Figure 1.9. The application of BNCT in a hospital setting [164]. 
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1.6.2 Type of cancer treated with BNCT 
BNCT treatment has mainly been focused on gliomas, but other cancers have also been 
investigated, such as head and neck, and liver cancers [28]. Also, non- malignant diseases, 
such as rheumatoid arthritis, are useful in BNCT treatment [165]. Penetration of the low-
energy thermal neutron beam, from a nuclear reactor, through tissues is the limiting factor 
[166]. GBM brain tumours have been regarded as the most appropriate for research study 
owing to its aggressiveness [167] and poor prognosis [165]. The high mortality seen in 
incidences of lung cancer [165] prompt a wide-spectrum use of BNCT for this cancer type 
[168,169]. A majority of patients with lung cancer would die from this disease if there was 
no other way of treatment other than surgical excision of the affected cancer part of the 
lung [165]. BNCT is therefore an attractive therapeutic approach [170]. 
 
1.6.3 Early history of BNCT 
Despite the apparent simplicity of BNCT, the technique has had a chequered history, with 
progress encountering a number of barriers. The first BNCT treatment was performed on a 
glioma patient in 1951 [171] and was followed by the treatment of around 40 patients into 
the early 1960s [172]. Many of these patients, however, suffered from scalp 
radiodermatitis. In the US, BNCT was carried out on 18 patients using the less toxic and 
more boron-rich compound disodium decahydrodecaborate (Na2B10H10), although many 
resulted in brain necroses and interest in the technique declined in the US for a while. 
Japan continued with BNCT in a clinical setting in 1968 using disodium 
mercaptoundecahydro-closo-dodecaborate (BSH; Na2B12H11SH) [163]. Here, the tumour 
was treated with BNCT during an operative procedure and this increased the 5-year 
survival rate of the patent giving renewed hope for the technique [173]. Since then BNCT 
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has increased in popularity, although has never become mainstream owing to problems 
associated with poor tumour selectively, accessibility of thermal neutron beams in a 
hospital environment (rather than a nuclear reactor), neutron beam penetration issues and 
lack of randomised clinical trials with equivocal demonstration of therapeutic efficacy 
[28,163]. 
 
1.6.4 Boron actives for BNCT 
The quest for new boron-containing compounds for use in BNCT has continued since the 
conceptualisation of the technique. These molecules generally fall into first, second and 
third generation compounds. 
 
1.6.4.1 First generation compounds 
In the 1950s, sodium borate (Borax), boric acid and pentaborates were used in BNCT to 
meet the demand for low toxicity, high tumour uptake and tumour concentration of 20 μg 
10B g-1 (per gram of tumour) [174]. Despite these conditions, however, patients still 
suffered from disease recurrence [175], mainly owing to the poor tumour retentions and 
attained and low tumour/brain ratios [175]. Consequently, in the 1960s, various arylboronic 
acids were used that had lower toxicities, increased tumuor/brain concentration ratios and 
had good retention abilities [176]. Para-carboxyphenylboronic acid (PCPB) was marked as 
being particularly promising [177]. 
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1.6.4.2 Second generation compounds 
BSH and boro-phenylalanine (BPA; 1,4-dihydroxyborylphenylalanine) are second 
generation boron compounds and have both passed clinical trial stage (Figure 1.10) 
[158,178]. 
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(a)       (b) 
Figure 1.10. Chemical structures of (a) BSH and (b) BPA. 
 
BSH and BPA are both effective in selective tumour cells uptake. The former compound 
was initiated by Hatanaka’s group and has been applied successfully for the treatment of 
human glioblastoma in BNCT [179,180]. BSH has a higher %B than first generation 
compounds and has a low toxicity.  
 
BPA is an analogue of the amino acid phenylalanine. The large uptake of amino acids by 
rapidly dividing cancer cells provides the mechanism for the specific incorporation BPA 
into cancer cells [181]. BPA was used at any early stage in the BNCT treatment of 
melanoma [182]. 
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1.6.4.3 Third generation compounds 
Carboranes, caged molecules based on boron, exhibit high molar boron content, neutral 
charge and good stability [183]. They are therefore ideal candidate molecules, the third 
class of compounds, for use in BNCT [184]. These molecules, however, are highly 
hydrophobic, making their delivery through the physiological medium very difficult 
[184,185]. 
 
Carboranes may be synthesised by the reaction of acetylene, or its derivatives, with boron 
hydrides. The polyhedral structure of carboranes exhibits three different forms: ortho, meta 
or para (Figure 1.11) [178,186]. The carboranes are regarded as biocompatible materials 
[187] and their anions confirm little coordinating power [188], but for application in 
BNCT, structural modifications are often necessary to improve the aqueous solubility of 
these molecules [187,189]. The ionic carborane derivatives have the ability to target 
tumour cells for BNCT [190]. 
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(a)    (b)    (c) 
Figure 1.11. The three isomers of carborane: (a) ortho-carborane (1,2-C2H12B10), (b) meta-
carborane (1,7-C2H12B10), and (c) para-carborane (1,12-C2H12B10);  = BH,  = CH. 
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1.7 The blood brain barrier 
Over a century ago, Paul Ehrlich (1885) demonstrated that many water-soluble dyes 
injected intravenously into the blood circulation were unable to pass into the brain [191]. 
His successor, Goldman (1913) injected dyes into the CFS and found that the brain has 
been stained but did not include peripheral organs, suggesting only small molecules could 
pass through what became known as the blood brain barrier (BBB) [192]. This structure 
impedes the influx of materials from blood to the brain, with brain blood capillary 
endothelial cells causing the low permeability due to tight junctions (Figure 1.12) [193]. 
The barrier is important for the regulation of the homeostasis of the brain's (neural) 
microenvironment of ions, nutrients and signalling and prevents entry of pathogens [194]. 
The BBB, however, has proven to be a bottle neck for the delivery of therapeutic agents to 
the brain to treat a variety of central nervous system disorders [195-197]. 
 
The BBB consists of three types of cell membranes: the endothelium (or basal-membrane; 
connected with tight-junctions, TJs), pericytes (necessary in angiogenesis regulation and 
endothelial proliferation) and astrocytes (which stimulate BBB properties in the endothelial 
membrane) [198]. The TJs are an important part of the integrity of the BBB [199]; they, 
along with biological mechanisms, inhibit the free diffusion of blood-borne solutes from 
the blood into the brain [200-204]. An efflux system further enhances the BBB by 
pumping drug molecules out of cells [197,200,205-207]. For these reasons, fewer than 5% 
of known drug molecules are able to reach the brain, regardless of their potential in vitro 
[208]. 
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Figure 1.12. Schematic showing the cells and tight junctions that comprise the BBB [209].  
 
1.7.1 Transport pathways across the blood-brain barrier 
The BBB acts as both a physical and biological barrier for regulating and maintaining 
important nutrients and essential materials in the brain (Figure 1.13) [201]. The TJs 
between neighbouring endothelial cells provide the physical barrier. This forces most 
molecular traffic to take a transcellular route across BBB instead of allowing paracellular 
movement. The biological barrier is essentially the layer of endothelial cells and their cell 
membranes that have various receptors (‘gatekeepers’) and mechanisms for allowing the 
influx and efflux of important endogenous biomaterials (substrates), such as sugars, amino 
acids, nucleotides and inorganic ions [203,210-214]. Small hydrophobic molecules, such as 
barbiturates and ethanol, are able to use the transcellular route. Small gaseous molecules 
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(O2, CO2) are also able to use this route. Hydrophilic molecules, large and small, such as 
histamine, peptides and proteins, are not able to pass via the transcellular route. 
 
Figure 1.13. Schematic diagram of the transport pathways across the BBB [215]. 
 
The BBB prevents systemic chemotherapy to the brain and central nervous system. 
Strategies for brain drug delivery may be broadly classified as being either neurosurgical-
based (invasive), pharmacologic-based, or physiologic-based. 
 
For biomolecules to successfully cross the BBB through passive diffusion, high lipid 
solubility and a molecular mass range of 400 – 500 Da are required. Since small molecules 
do not normally penetrate the BBB [211,216,217], much recent research has been focused 
on developing biomaterial-based nano- and microcarrier systems for drug delivery [218]. 
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These have included the use of liposomes [219-224], since they are small (ca. 100 nm), 
biodegradable and can protect the active drug from degradation [225-227].  
 
1.8 Liposomes 
For effective delivery of drugs to the brain, many approaches are under investigation, 
including modulation of BBB, inter-cerebral infusion/injection, nanoparticulate drug 
delivery, the use of pro-drugs, chemical delivery and delivery via liposomes [228]. 
Research efforts towards liposome-facilitated drug delivery are rationalised in terms of the 
biodegradability, non-toxicity, non-immunogenicity and also in terms of their capacity to 
accommodate a wide range of drug molecules, irrespective of hydrophilicity [229,230]. A 
good drug delivery system ensures that the active drug is present at the site of action at the 
right time and for right duration [228]. Drug carriers are necessary in pharmaceutical 
formulations for many reasons [231]: (a) to enhance drug targeting [228], (b) to overcome 
solubility issues, (c) to protect drugs (such as protein and DNA) from undesired 
interactions that could lead to hydrolysis, enzymatic degradation, loss of original structure 
or activity, and (d) reduce drug toxicity. 
 
Drugs can be chemically modified using pro-drug techniques or by making use of a 
biological carrier system/drug delivery vehicle [232], which can be divided into two major 
groups: soluble carrier systems and particulate carriers. The former may comprise of 
natural or synthetic water soluble polymers, where drugs are conjugated to the delivery 
vehicle. Examples of the latter system include liposomes, microspheres and nanoparticles, 
where the drug is either surface-bound or entrapped within the carrier. 
Chapter 1: Introduction 
32 
 
The physiological environment of the targeted site plays an important role in drug targeting 
as the drug may accumulate naturally at the targeted site (passive targeting). Alternatively, 
drugs can be targeted to the site using target-specific recognition components, e.g., the 
addition of a galactose group to a drug carrier system can enhance targeting of galactose 
receptors on the surface of liver cells (active targeting) [228]. 
 
1.8.1 Structure of liposomes 
Liposomes are artificially prepared vesicles made of a lipid bilayer [233,234] and are 
composed of naturally-derived phospholipid bilayers with mixed lipid chains [235,236] 
(Figure 1.14). Their size may vary from 30 nm to many micrometres [237]. Phospholipids 
are a class of lipid which occur naturally as biomolecules that play an important role in 
human physiology, serving as components of biological membranes. The hydrophilic head 
is the phosphate group which is negatively charged and the hydrophobic tail is a fatty acid. 
Phospholipids are cholesterol-like compounds found in all layers of the skin, except the 
stratum-corneum [237,238]. Asymmetrical phospholipids are commonly used for 
liposomal dispersion (Figure 1.14b) [228,238]. The biphasic properties of liposomes make 
them attractive as a vehicle carrier for both lipophilic and hydrophilic drugs. This enables 
them to have different time latencies and retention capacities [239].  
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(a) 
 
(b) 
Figure 1.14. Idealised structures of (a) liposomes and (b) phospholipids [237]. 
 
 
Liposomes are classified according to their size, lamellarity and numbers of bilayers or 
vesicles [240]. For example, liposomes may be unilamella (small unilamella, SUVs, < 100 
nm; or large unilamella, LUVs) or multillamella, MLV. SUVs are circular in shape 
(typically 20 nm in diameter) [240] and are homogenously distributed which makes them 
unique among other vesicles [241]. The low encapsulation efficiency (ca. 0.1 – 1 %) 
reduces their capacity as drug vehicles. LUVs (> 100 nm) have high encapsulation 
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efficiencies [242]. MLVs are up to 5 or more bilayers (diameter > 100 nm) and may 
contain SUVs and/or LUVs; their encapsulation capacity is generally poor. 
 
Further variation in liposome structure and properties can be achieved using various 
inclusions and graftings (Figure 1.15). Conventional liposomes, so far outlined, are 
comprised of phospholipids in an aqueous compartment that form lipid bilayers. Rigidity 
can be improved by the addition of cholesterol (Figure 1.16) [243]. 
 
Figure 1.15. Different types of liposomes. Components: phospholipids (blue), PEG lipid 
(orange), antibody or targeting ligand (red), cationic lipid/helper lipid (black cross). 
Adapted from [237]. 
 
The bilayers they form consist of hydrophilic and hydrophobic layers, which make it 
possible for the encapsulation of lipophilic drugs in the hydrophobic area and also for 
lipophilic (hydrophobic) drugs to be encapsulated in the hydrophilic region. PEGylated (or 
long circulating) liposomes have their surfaces coated with a polyethylene glycol (PEG) 
that allows them to resist being coated with opsonin, a plasma protein which makes 
liposomes more easily recognised by the reticuloendothelia system or mononuclear 
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phagocytic system (MPS) in the liver, causing longer circulation and release profiles 
[234,244]. With PEGylated liposomes, the circulation time is not dependent on the dose 
administered [245]. Other liposome types include targeted liposomes (ligand bearing or 
immunoliposomes – those involving targeted antibodies as ligands), cationic liposomes 
(for genetic material delivery) and deformable/elastic liposomes. 
OH
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Figure 1.16. Chemical structure of cholesterol. 
 
1.8.2 Use of liposomes for chemotherapy 
Liposomes are ideally suited for nano-drug delivery systems: actives may be entrapped 
within the lipophilic or hydrophilic regions within the liposome structures [149,246-248]. 
A promising application is based on the uptake of liposomes by the reticuloendothelial 
system (RES) for treatment of infection or for vaccination. Liposomes have been used for 
treating infections [249-251], developing vaccines [252-254] and gene delivery [244]. 
 
In addition, the ability of SUVs to persist in the circulatory system serves as an access into 
neoplastic tissue [235,255,256]. This is important for developing novel chemotherapy 
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techniques [246], where higher efficiencies for delivering toxic tumouricidal agents to the 
tumour are required [257]. Encapsulation of potent drugs in liposomes reduces their toxic 
adverse side-effects [258]. 
 
Almost all anti-cancer drugs have been encapsulated in liposomes using diverse 
technologies [259]. The suitability of liposomes to act as anticancer drug carriers depends 
on the potency of the drug they carry [260]. The successful encapsulation of doxorubicin 
and daunorubicin in liposome has resulted in two products – doxil and daunoxome [258], 
which have been clinically approved [259] for the treatment of Kapos’s sarcoma [261]. 
Over-expressing cells have also been targeted using immunoliposomes [262] and 
thermosensitive liposomes [263]. 
 
1.8.3 Drug delivery to the brain using liposomes 
Therapeutic drug delivery to the brain through the intravenous route is problematic due to 
the blood-brain-barrier (BBB), a physiological natural barrier that restricts the number of 
potential drug molecules from entering the brain. Small (MW < 400 – 600 g mol-1) 
lipophilic compounds are able to diffuse across the BBB, but most drugs in the circulatory 
system are not able to pass through [264]. Immunoliposomes (antibody-directed 
liposomes; Figure 1.15) provide a method of site-specific drug delivery providing steps are 
taken do reduce their rapid clearance by the retroendothelial system, such as PEGylation 
[265]. Huwyler et al. encapsulated daunomycin, an anti-cancer agent, into PEGylated 
liposomes (85 nm), each coupled to 30 OX26 antibodies [266,267]. These were found to 
accumulate successfully in brain tissue, overcoming the BBB limitation. Similar transport 
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across the BBB was achieved with liposomes (< 100 nm) containing various nerve growth 
factors (NGFs; 34% encapsulation) [268].   
 
1.8.4 Use of liposomes for BNCT 
Liposomes are ideal carrier systems as they accommodate large numbers of boron 
containing species for selective delivery to neoplastic tissues [149,267]. Boronated 
compounds may be inserted within the vacant polar inner space of liposomes or, in the case 
of polyhedral boranes, encapsulated within the lipid double-layers [267,269]. The in vitro 
delivery of boron species by a liposomal carrier was introduced by Yanagie et al. [270]. A 
number of methods, systems and species have been explored. 
 
Pan et al. passively entrapped BSH and an amino-boron compound Na3(B20H17NH3) into 
folate receptor (FR)-targeted SUV PEGylated liposomes for specific delivery, achieving 
encapsulation efficiencies of 6 and 15%, respectively [271]. Boronated polyamine 
derivatives were also investigated. The FR-targeted liposomes delivered large quantities of 
boron to tumour cells (1584 µg/10
9
 cells), exceeding the lethal dose (20-35 µg/g tumour). 
The same amino-boron compound entrapped in PEG-2000-distearoyl 
phosphatidylethanolamine liposomes was investigated by Feakes et al. [272]. As with most 
PEGylated liposomes, long circulation times were observed, with a peak concentration of 
47 µg of B/g tumour being reached after 48 h. Awad et al. studied interactions between 
BSH and liposomes that offered suggestions for the strong binding and intracellular uptake 
(cancerous tissue is rich in choline) of this boron species in glioblastoma patients prior to 
BNCT [186]. 
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Justus et al. used double-tailed lipids covalently bound to carboranes, producing a double 
negatively charged head group, to making liposomes [273]. These were found to be less 
toxic than (B12H11S)
2-
, the only acceptable cluster compound, and used in clinical trials in 
Japan, at the time of the investigation. Miyajima et al. also produced double-tailed boron 
lipids and thus liposomes [274]. Transferrin (Tf) was loaded into the PEGylated liposomes 
to induce specificity, since the Tf receptor is upregulated in tumour cells. Nakamura et al. 
synthesised a nido-carborane lipid and incorporated this into 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC)/cholesterol/PEG based liposomes [275]. Li et al. produced a 
similar boronated, two-tailed lipid and highlighted that the absence of need for DSPC, high 
B loading rates could be achieved [276]; unfortunately, in this particular case, the lipid was 
found to be cytotoxic in vivo.  
 
Another approach has been to covalently attach carboranes to cholesterol that is used to 
prepare the liposomes, as investigated by Feakes et al. [277]. The nido-form provided 
further negative charge on the liposomes exterior and was thought to contribute to the 
enhanced tumour specificity. Thirumamagal et al. also made three carboranyl cholesterol 
derivatives, with the boron cages replacing the B and C rings of cholesterol, one compound 
of which was stably incorporated into the liposome; low cytotoxicity was demonstrated 
[278]. 
 
Martini et al. incorporated BPA into mixed neutral (zwitterionic) and cationic liposomes 
and analysed the location of this boronated molecule [279]. The boron-substituted aromatic 
ring was maintained in the hydrophobic region, with the amino group oriented out towards 
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the polar head exterior. Altieri et al. found cationic liposomes, using two carborane 
derivatives, to be at least 30× more effective in terms of achieving cellular 
10
B 
concentrations as uncharged carriers [280]. Salvati et al. incorporated a carborane 
containing eight closed icosahedral cages into various liposomes made from positive, 
negative and neutral phospholipids [231]. The latter zwitterionic liposomes, in this study, 
were found to uptake the carborane species in higher quantitities. 
 
1.9 Project aims  
The three main aims of this project are: 
1. To formulate, characterise and evaluate the efficacy of a liposomal-based delivery 
system containing a model carborane (o-carborane) for BNCT that would be 
sufficiently small (< 100 nm) to potentially cross the BBB (Chapter 2); 
2. To derivatise a carborane with a mitochondrial dye (a delocalised lipophilic cation) 
that shows specificity for cancer cells (based on mitochondrial membrane 
potentials) in order to make a targeted BNCT molecule and then to test its efficacy 
in vitro using cancer and control cells (Chapter 3); 
3. To investigate the use of a spray-dried o-carborane formulation for use in BNCT 
treatment of cancer.  Since the particle size will be > 100 nm and therefore unable 
to transport across the BBB, the microparticles may have potential for BNCT 
treatment for liver and lung cancer; the latter being particularly attractive since the 
spray-dried formulation could be delivered as an inhaled powder to the lungs, 
providing further targeting (Chapter 4).  
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This project adds to and complements work carried out by the research supervisors and 
their collaborators, notably Dr Dimitris Fatouros (University of Thessaloniki, Greece), Prof 
Sophia Artimisiaris (University of Patra, Greece) and Dr Gianpiero Calabresse (University 
of Kingston, UK). The novelty/contributions to knowledge resulting from this PhD work 
are highlighted in Chapter 5. 
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Chapter 2 
Liposomes loaded with o-carborane for BBB delivery 
2.1 Introduction 
2.1.1 Preparation of liposomes using the thin film method 
Liposome properties are determined by lipid composition, size, surface charge (zeta 
potential; -potential) and method of preparation [1]. For the latter, these include the: thin 
film method, sonication method [2], injection method [3,4], extrusion method [5], French 
press method [6], microfludisation method, reverse-phase evaporation method [7,8], 
dehydrated – rehydrated vesicle method [9,10], giant vesicle method [10,11], detergent 
depletion method [12,13], large unilamella vesicle from Cochleate method [14], and one 
step method [15]. The thin film method, described below, is one of the most common and 
is used in this thesis. 
 
Lipids are mixed with chloroform or methanol and a high-vacuum rotor evaporator pump 
is used to remove the organic solvent to form a thin film around the walls of the flask 
[16,17]. The aqueous phase for the thin film to be re-hydrated must be pre-warmed to just 
above the phase transition temperature for the lipid (related to carbon chain length and 
liposome rigidity). This solution is then agitated to allow removal of the lipid thin film 
from the wall of the flask. MLVs are then produced. Drugs to be encapsulated may be 
added to the solution after re-hydration. 
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2.1.2 Characterisation of liposomes 
Liposomes are also characterised in terms of their size, size distribution, -potential, 
stability and trapping efficiency of any incorporated moiety/drug, as detailed below [18]. 
 
2.1.2.1 Liposome size 
Dynamic Light Scattering (DLS), using a Nanosizer or Zetasizer, is typically used to 
characterise liposome particle sizes. The Zetasizer determines the size of particles by 
measuring the speed of their movement caused by Brownian motion in a liquid. The speed 
is used to calculate the hydrodynamic particle diameter (DH) using the Stoke-Einstein 
equation (Equation 2.1),  
𝐷𝐻 =
𝑘𝑇
𝑓
=
𝑘𝑇
3𝜋𝐷
        (Equation 2.1) 
where k = Boltzmann constant, T = absolute temperature, f = particle frictional coefficient, 
 = solvent viscosity and D = diffusion coefficient. 
 
Large particles move slowly whilst smaller ones move more rapidly. Size extrusion 
chromatography is another widely used method [19,20]. The polydispersity index (PDI) 
(Equation 2.2) provides a measure of the variation in particle size of a sample. The value is 
between 0 and 1, 0 being that of a perfectly monodispersed distribution, 
𝑃𝐷𝐼 =
𝜎2
𝐷𝐻
2         (Equation 2.2) 
where σ = standard deviation of the distribution (nm) and DH = hydrodynamic diameter. 
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2.1.2.2 Surface charge of liposomes 
The surface charge on liposomes can be measured from the -potential (mV). When a 
charged particle is suspended in an ionic liquid, oppositely charged ions are strongly 
attracted and surround the charged particle. Other ions far out in the solution are less 
attracted and form a diffuse layer (Figure 2.1). In this layer, there is an imaginary boundary 
and ions within it will travel along with the particle as moves in the liquid. However, ions 
outside the boundary will not move and this is known as the slipping plane. -Potential is a 
potential that occurs between the particle surface and the dispersing liquid that depends on 
the distance from the particle surface. It is the potential at the slipping plane and is 
measured using the Helmholtz-Smoluchowski equation (Equation 2.3) [21], 
 =
4𝜋𝜇
𝐷
         (Equation 2.3) 
where  = electrophoretic mobility,  = viscosity and D = dielectric constant of the 
medium at the boundary. 
 
The -potential is the degree of repulsion between the particles; the higher the values, in 
either positive or negative direction, the more the stable the particle. Limits of -31 or +31 
mV are often used, where agglomeration is expected between these values. 
 
The outer surfaces of liposomes have the greatest impact on their physical stability, storage 
and in vivo studies. 
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Figure 2.1. A charged particle surrounded by oppositely charged ions. The -potential is 
the potential at the slipping plane. Adapted from [22]. 
 
2.1.3 Stability of liposomes 
Pharmaceutical products need a shelf life of 24 months and therefore the chemical and 
physical stability of liposome formulations are very important [23]. Phospholipids can 
hydrolyse to form fatty acids 1- and 2-acyl-lysophospholipid upon storage [24]. The 
complexing agent ethylenediamine tetraacetic acid (EDTA) can be used to minimise this 
problem. The rancidity of lipids can be reduced by α-tocophenol, which causes a reduction 
in auto-oxidation of lipids caused by the action of light, metal ions and temperature. 
Cholesterol can be used together with α-tocophenol to increase liposome shelf-life [25,26]. 
As a physical method for stabilising liposomes, freeze drying (cryoprotection) [27] and 
dehydration (lyoprotection) [28,29] may also be used. The amount of drugs liposomes are 
able to retain (retention) and the duration of their retention (latency), measures of 
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membrane integrity, are important parameters for storage and in vivo studies. They can be 
measured by quantitifying the release of calcein (Figure 2.2), a small-water soluble 
hydrophilic marker dye contained in the hydrophilic interior of the liposome, after the 
addition of Triton X-100 to disrupt the lipid bilayer (Equations 2.4 and 2.5) [30], 
 
% Latency =
DF (FAT−FBT)
DF .  FAT
× 100%      (Equation 2.4) 
where DF = dilution factor, FBT = fluorescence value before adding Triton X-100, FAT = 
fluorescence value after adding Triton X-100, and 
 
% Retention =
% Latency at t𝑥
% Latency at 𝑡0
× 100%     (Equation 2.5) 
where tx = time after a particular time period (e.g., 24 h), and t0 = initial time.  
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Figure 2.2. Chemical structure of calcein. 
 
A high latency means lower amounts of calcein has been released (higher encapsulation) 
before the addition of Triton X-100. The property is dependent on the integrity of the 
liposomal membrane, as well as the physical and chemical properties of the drug delivery 
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system. A high retention signifies larger calcein release (higher encapsulation) after the 
Triton X-100 addition. 
 
2.1.4 Aims 
The aim of the work outlined in this Chapter was to form small (< 100 nm dia.), stable 
SUV liposomes of dipalmitoylphosphatidylcholine (DPPC) and DSPC liposomes (Figure 
2.3), with and without cholesterol, incorporating o-carborane for BCNT. These novel 
particles, produced via the thin-film method, should have the potential to cross the BBB 
and avoid recognition by macrophages [31]. Stability was assessed in terms of -potential 
and retention of the hydrophilic marker calcein (Figure 2.2) in phosphate-buffered-saline 
(PBS, pH 7.4) and human serum. o-Carborane incorporation was measured using 
spectrophotometry (displacement of Nile Red, Figure 2.3c) and directly using inductively 
coupled plasma (ICP) mass spectrometry for 
10
B content. 
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Figure 2.3. Chemical structures of (a) DPPC, (b) DSPC, and (c) Nile Red. 
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2.2 Materials and methods 
The experiments were divided into three main sections: (a) preparation of DPPC and 
DSPC liposomes, using the thin-film method, incorporating different o-carborane volumes 
and assessing particle sizes, -potentials and stability; (b) increasing stability using 
cholesterol and assessing stability in near-physiological conditions (serum); and (c) 
measuring degree of loading (Nile Red entrapment and ICP-MS). 
 
2.2.1 Preparation of liposomes 
DPPC and DSPC were obtained from Lipoid, Germany. Potassium chloride, potassium 
phosphate K2HPO4, cholesterol, calcein, Nile Red and Sephadex G-50 were provided by 
Sigma-Aldrich (Dorset, UK). Syringe filters (0.2 μm, PES 25 mm; GD/X sterile) were 
obtained from Whatman. Ethanol, chloroform, sodium chloride, sodium phosphate 
NaH2PO4, sodium hydroxide and hydrochloric acid were obtained from Fisher Scientific 
(Loughborough, UK). NaOH (20%) and HCl (2M) were prepared in the laboratory. o-
Carborane was obtained from Alfa Aesar, UK. 
 
2.2.1.1 Preparation of phosphate buffered saline (PBS, pH
 
7.4) 
PBS (1 L) was made containing NaCl (8.00 g), KCl (0.19 g), KH2PO4 (0.2 g), Na2HPO4 
(1.7 g) and adjusted to pH 7.4 using NaOH (20%) and HCl (2M). 
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2.2.1.2 Preparation of calcein stock solution 
Calcein stock solution (50 mM) was prepared by dissolving calcein (0.3113 g, 622.55 g 
mol
-1
) in distilled water (ca. 8 mL) with dropwise addition of NaOH (10% w/v) until the 
powder was completely dissolved. The pH of the calcein solution was adjusted to pH 7.4 
(with addition of 2M HCl, if necessary). The solution was then made up to 10 mL, filtered, 
placed in an amber bottle wrapped in aluminium foil and stored in the fridge (4 °C). 
 
2.2.1.3 Preparation of serum stock solution from rat blood 
Plasma stock solution was made using whole blood: rat blood (20 mL) was placed in a 
beaker and left for ca. 30 min to clot. This was facilitated by placing it in an incubator (37 
°C for 30 min). A long Pasteur pipette was used to separate the clotted blood from the wall 
of the beaker. The clotted blood was then transferred into separate Eppendorf tubes, cooled 
(4 °C, 10 min) and centrifuged (3000 rpm, 10 min) to separate the plasma from the blood. 
The serum appeared as a clear yellowish colour liquid on top of the clotted blood. The 
serum was then transferred into new Eppendorf tubes using a plastic pipette. This was then 
further centrifuged (3000 rpm, 10 min) to allow further clearing of the plasma and the 
separated serum was placed in Eppendorf tubes and stored in the freezer for future use. 
 
2.2.1.4 Preparation of Nile Red stock solution 
For assessment of liposome o-carborane loading, a Nile Red solution in CHCl3 was 
required to disperse the lipids before forming the thin-film. The final concentration of Nile 
Red in the lipid dispersion was required to be 2.5 μM, with a final dispersion volume of 3 
mL (3 mL × 3 (for triplicates) = 7.5 × 10
-3
 µmoles = 2.5 × 10
-3
 µmoles ml
-1
, required for 
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the final dispersion). To achieve this, a stock solution of Nile Red (2.39 μg mL-1 = 7.5 × 
10
-3
 µmoles × 318.38 g mol
-1
) in CHCl3 was prepared as follows: Nile Red (3.6 mg) was 
dissolved in CHCl3 (15 mL) to make Solution 1 (0.24 mg mL
-1
); CHCl3 (9 mL) was added 
to an aliquot of Solution 1 (1 mL) to make Solution 2 (23.9 µg mL
-1
); CHCl3 (9 mL) was 
added to an aliquot of Solution 2 (1 mL) to make the stock Nile Red Solution (2.39 µg mL
-
1
). This was then wrapped in foil and placed in the fridge (4°C). 
 
2.2.1.5 Preparation of o-carborane stock solutions 
In accordance with the literature method 
1
, the lipid : o-carborane molar ratios were mixed 
to be 1:0.5, 1:1, 1:10, 1:20 and 1:40. These were prepared using DPPC and, separately, 
DSPC (15 mg) to achieve a final lipid concentration of 5 mg mL
-1
. The concentrations 
were thus, for DPPC = 5 mg mL
-1
 / 734 g mol
-1
 = 6.812 × 10
-3
 mmol mL
-1
 = 6.8 mM, and 
for DSPC = 5 mg mL
-1
 / 790.15 g mol
-1
 = 6.3 × 10
-3
 mmol mL
-1
 = 6.3 mM. To obtain the 
required lipid : o-carborane molar ratios of 1:0.5, 1:1, 1:10, 1:20 and 1:40, the 
concentrations of o-carborane needed were therefore 3.4, 6.8, 68, 136 and 272 mM, 
respectively, for the DPPC lipid, and 3.2, 6.3, 63, 126 and 252 mM for the DSPC lipid. In 
the case of the lowest o-carborane concentration (3.4 mM) for the DPPC lipid, the mass of 
o-carborane = 3.4 × 10
-3
 mmol mL
-1
 × 3 mL = 10.2 × 10
-3
 mmol in 3 mL = 10.2 × 10
-3
 × 
144.23 g mol
-1
 = 1.5 mg o-carborane in 3 mL dispersion. Similarly, for all the o-carborane 
solutions for the required ratios (1:0.5, 1:1, 1:10, 1:20 and 1:40), the mass of DPPC and 
DSPC were 1.5, 3.0, 30, 60 and 120 mg, and 1.4, 2.8, 28, 56 and 112 mg, respectively. 
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Two stock o-carborane solutions to prepare the dilutions for the DPPC and DSPC lipids 
were produced, as follows. For the highest mass (120 mg), 1 mL of CHCl3 was required, 
and therefore, for the total mass (1.5 + 3.0 + 30 + 60 + 120 mg = 214.5 mg), for the DPPC 
lipids, the required CHCl3 volume = 214.5 mg / 120 mg × 1 mL = 1.788 mL; this volume 
was then added to o-carborane (214.5 mg). Similarly, 220.2 (1.4 + 2.8 + 28 + 56 + 112) mg 
/ 112 mg × 1 mL = CHCl3 (1.788 mL) was added to o-carborane (214.5 mg). These 
Eppendorf tubes were then wrapped in foil and placed in the fridge (4°C). 
 
2.2.1.6 Preparation of DPPC/DSPC liposomes using the thin-film method  
DPPC and DSPC liposomes were prepared using the standard thin-film hydration method: 
DPPC/DSPC (250 µL) from the stock solution (200 mg per 10 mL, 20 mg mL
-1
) 
2
 were 
placed into three separate flasks. This gave a lipid mass of 5 mg (DPPC, 6.8 mM; DSPC, 
6.3 mM 
3
), required for the low systemic toxicity and normal tissue uptake, equivalent to 
ca. 20 µg / 
10
B / g tumour). The organic solvent was evaporated under reduced pressure 
(Buchi 461 rotary evaporator, Switzerland) at a temperature 10 °C > lipid phase transition 
temperature (chain melting temperature, Tc = 42 °C DPPC, 54 °C DSPC [35]) and then 
dried (N2 stream) [33,36] to yield thin films at the air-water interface. These were 
rehydrated at 60 °C with PBS (3 mL; buffer solution, pH 7.4) and dispersed using a vortex 
[33] to produce empty liposomes [37]. 
 
Loaded liposomes were prepared using calcein (3 mL; 50 mM) that was pre-warmed > Tc 
of DPPC (45 °C; 10 min) and added to the prepared thin film. This dispersion was 
vortexed (5 min) to assist uniform dispersion. To decrease the size of liposomal 
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dispersions, the mixture was placed in the bath sonicator (30 min) [33,36]. The round-
bottomed flask was placed at the air-water interface in the sonicator to ensure optimal 
particle size reduction [38]. 
 
For the preparation of SUVs, the suspension was subjected to probe sonication (120 s at 2 s 
intervals; Gex 400 Probe Sonicator, Germany) [39]. To remove of Ti fragments, MLVs or 
liposomal aggregates, the liposome dispersion was centrifuged (5 min; 3000 rpm). The 
samples were then annealed [39] for at least 1 h at the liposome preparation temperature 
(50-60 °C; above their Tm in the water bath) to remove any structural disabilities [39] 
before loading them onto the prepared gel-chromatography columns. 
 
For the addition of cholesterol, the lipid : cholesterol ratio was maintained at 2:1, i.e., 500 
µL : 250 µL, to make 750 µL for all 3 columns (250 µL  5 mg per column). For the 
absence of cholesterol, 750 µL of lipid was used. The lipid (+ cholesterol) was placed in a 
round-bottomed flask and the CHCl3 removed. 
 
2.2.1.7 Preparation of DPPC/DSPC liposomes for fluorescence displacement, particle 
size measurements and ICP-MS 
DPPC and DSPC liposomes containing o-carborane, as with the unloaded liposomes, were 
prepared using the same thin-film hydration method as provided in Section 2.2.1.6. 
Different volumes of o-carborane stock solution (0, 12.5, 25, 250, 500, 1000 µL; Section 
2.2.1.5), CHCl3 (1 mL) and Nile Red (1000 μL; Section 2.2.1.4) were pipetted into a 
round-bottomed flask. The solvent was removed under reduced pressure (Buchi Rotavapor 
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R) to yield a thin-film. The remainder of the procedure was carried out as outlined in 
Section 2.2.1.6.  
 
2.2.2 Calcein stability measurements 
Sephadex G-50 (10 g) was dispersed in PBS (200 mL) and air bubbles removed by 
sonication (30 min; FS400 Decon ultrasonic bath, Germany) before loading into empty 
Sephadex G-50 columns (1 cm × 35 cm; n = 3) [33,39-41]. To render calcein-loaded 
vesicles osmotically stable, non-encapsulated calcein was separated from liposomes 
containing calcein (Section 2.2.1.6) on a Sephadex G-50 column (gel-permeation-
chromatography, Anachem, UK) using PBS (pH 7.4) as the eluent (Figure 2.4); pre-
saturation of the column with each lipid, allowed recoveries > 94% [42]. 
    
(a)         (b) 
Figure 2.4. (a) Sephadex G-50 columns used in gel permeation chromatography (n = 3), 
and (b) schematic showing separation of encapsulated (liposomes) and non-encapsulated 
calcein. 
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Prior to any liposome sample measurements, the fluorescence intensity (em = 495 nm, ex 
= 520 nm; Varian Inc., USA) of PBS (blank, pH 7.4) was measured (cuvette). Samples 
from the 3 columns (S1, S2, S3) were placed in a water bath (37 °C). An aliquot of each 
solution (40 μL) was placed into separate Eppendorf tubes containing PBS (4 mL; pH 7.4) 
[39]. The fluorescence intensity was measured immediately (t0 = 0 h). The solution was 
transferred into the original Eppendorf tube, Triton X-100 (10%; 400 μL) added and the 
tube agitated (electrical vortex, 5 s, 2000 rpm) to break down the liposomes and release the 
encapsulated calcein [32,39]. The fluorescence was then re-measured. This was repeated 
after time intervals of 1, 2, 3, 4, 5, 6, 7, 8, 9, 12 and 24 h. 
 
For fluorescence measurements in serum, a similar method was used. A blank fluorescence 
reading was obtained from a solution of serum (125 μL) in PBS (500 µL; pH 7.4). The 
combined volume of samples from the columns were divided by 4 and used for each 
reading, i.e., 200 μL of sample was obtained from each column, and 50 μL of serum used 
for each reading. Fluorescence measurements (cuvette) and the procedure for adding Triton 
X-100 were performed as above, after adding the sample (40 μL) to PBS (4 mL, pH 7.4). 
 
Sample dilution (1 mL in PBS, 1 mL; pH 7.4) was necessary when fluorescence 
measurements were > 700 for the initial and final measurement, i.e., before and after the 
addition of Triton X-100. 
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%Latency and %retention of liposomes, with and without cholesterol, in serum at 37 °C 
were calculated at time intervals of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 h (Equations 
2.4 and 2.5, Section 2.1.3). In Equation 2.4, DF = 1.1.   
 
A paired t-test was used to evaluate statistical differences between % latency and 
%retention results. A probability value < 0.05 was considered to be significant. 
 
2.2.3 Nile Red entrapment measurements 
The fluorescence intensities of liposomal solutions containing Nile Red were measured 
under identical conditions to those stated for the calcein content measurements (em = 495 
nm, ex = 520 nm; Varian Inc., USA; Section 2.2.2). 
 
2.2.4 Particle sizing and ζ-potential 
Dynamic light scattering (DLS; measurement angle, 173 °) data were obtained for 
liposomes with and without entrapped o-carborane and electrophoresis measurements 
performed using a Nano-ZS Zeta at 25 °C (4 mW He-Ne laser  = 633 nm, photodiode 
detector; Malvern instrument, UK). The PDI (Section 2.1.2.1) and ζ-potential (Section 
2.1.2.2) were also recorded at 25 °C. 
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2.2.5 ICP-MS Boron analysis 
An aliquot of conc. sulphuric acid (500 μL) was added to each of the liposome solutions 
(600 µL; each liposome formulation (3 mL) containing o-carborane, 0, 12.5, 25, 250, 500 
and 1000 μL) in boron-free glass vials. The solutions became darkened and were allowed 
to cool to 24 °C (very important due to the exothermic reaction in the next step). Hydrogen 
peroxide (100 µL) was then added to each tube and when the solutions became 
decolourised, the volumes were adjusted to 2 mL by addition of distilled water (800 μL). 
The 
10
B content of the mineralised (‘digested’) samples and supernatant were then 
determined using an inductive coupled plasma-mass spectrometer (ICP-MS; Agilent 
Technologies,700 Series) operating at 1550 W, with a carrier gas flow rate of 0.91 L min
-1
, 
make up gas flow of 0.24 L min
-1
 and a nebuliser pump rate of 0.1 rps. Beryllium and 
10
B 
standard solutions (1000 ppm) were used in the calibration. 
 
2.2.6 Scanning electron microscopy 
An aliquot of a solution containing DSPC liposomes (5 µL), unloaded and o-carborane 
(1000 µL) loaded, was placed on a surface of freshly-cleaved muscovite mica (Agar 
Scientific, Stansted, Essex, UK) and left to dry for 2 min. The surface was then rinsed with 
distilled water, dried in a N2 stream and sputter-coated with Au/Pd in an Argon atmosphere 
(< 0.2 Torr, 18 mA for 5 – 10 min; Polaron E5000 SEM coating-unit, Quorum 
Technologies Ltd., East Grinstead, UK). SEM imaging was performed immediately using a 
JEOL JSM-6060LV SEM instrument (resolution = 4.5 nm, acceleration voltage = 15 kV). 
Particle sizes were obtained from the scale bar and means and SDs determined.  
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2.2.7 Atomic force microscopy 
Liposome samples were prepared as for SEM (Section 2.2.6), although without Au/Pd 
coating. Atomic force microscopy (AFM) studies were carried out using a Multi-
Mode/NanoScope IV scanning probe microscope, Bruker, Santa Barbara, CA, USA and 
were performed in air under ambient conditions (T = 23 °C, RH = 21%) using the J-
scanner (max. xy = 200 µm). Scanning was performed in Tapping mode using Si 
cantilevers with integrated tips (t = 3.6–5.6 µm, l = 140–180 µm, w = 48–52 µm, 0 = 288–
338 kHz, k = 12–103 N m-1, R < 7 nm; model: OTESPA, Bruker, France), and an RMS 
amplitude of 0.8 V. The images were subsequently processed and dimensions measured 
using NanoScope Analysis software (V 1.4, Bruker, Santa Barbara, CA, USA). 
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2.3 Results and discussion 
2.3.1 Particle sizing, PDI and ζ-potential 
The particle sizes, PDIs and ζ-potentials of the prepared DPPC/DSPC liposomes unloaded 
and loaded with o-carborane (0 to 1000 μL), and those that were probed once, were 
determined immediately after annealing using the zeta seizer are shown in Table 2.1.  
 
Table 2.1. Particle size, PDI and ζ-potential values for DPPC and DSPC liposomes with 
different volumes of incorporated o-carboranes. 
 DPPC, Mean ± SD DSPC, Mean ± SD 
Liposomes 
+ o-
carborane  
/ µL 
d / nm PDI ζ / mV d / nm PDI ζ / mV 
0 67.9 ± 5.1 0.27 ± 0.13 -3.41 ± 0.61 82.0 ± 7.0 0.234 ± 0.01 -4.14 ± 0.91 
12.5 74.7 ± 6.8 0.16 ± 0.07 -5.67 ± 0.30 86.3 ± 5.4 0.214 ± 0.07 -6.10 ± 2.14 
25 66.5 ± 8.1 0.18 ± 0.08 -1.84 ± 6.20 83.5 ± 7.9 0.177 ± 0.02 -8.64 ± 4.73 
250 73.7 ± 11.8 0.12 ± 0.02 -1.83 ± 3.35 89.5 ± 6.8 0.210 ± 0.02 -9.15 ± 0.17 
500 78.1 ± 9.0 0.26 ± 0.14 -6.50 ± 1.43 94.4 ± 6.8 0.199 ± 0.04 -12.07 ± 4.61 
1000 86.7 ± 11.7 0.18 ± 0.12 -5.02 ± 1.11 97.8 ± 3.5 0.192 ± 0.05 -9.84 ± 9.30 
 
The particle sizes are ca. 80 nm with those of DSPC being larger than those of DPPC. This 
was expected since the chain length of the former is larger than that in DPPC. Particle sizes 
were seen to increase linearly with increased o-carborane loading, suggesting successful 
incorporation. This has been observed elsewhere using different liposomes [34]. Since the 
particle sizes are < 100 nm, these liposomes show promise for delivery across the BBB 
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[44]. All PDI values, irrespective of o-carborane loading, were < 0.5 confirming a very 
evenly monodispersed, homogeneous particle size distribution (Table 2.1). 
 
The net particle charges on the prepared liposomes, as reflected by their ζ-potentials, are 
summarised in Table 2.1. All values were between -30 and +30 mV, indicating that the 
particles were not stable and therefore are likely to agglomerate. This is probably due to 
the high ionic strength of the PBS medium [34]. Awad et al. observed the ζ-potential to 
decrease sigmoidally, from -5 to -40 mV, with increasing BSH concentrations and 
attributed this to an interaction between the boron species and the lipid bilayer [32]. In the 
current study, the ζ-potential was found to decrease with increasing o-carborane loading, 
although this parameter is not concentration.  
 
2.3.2 Effect of re-probing on liposome properties 
To further decrease particle size, liposome formulations were re-probed. Table 2.2a and 
2.2b show the effect of re-probing (before and after, 5 min) the DPPC and DSPC 
liposomes loaded with o-carborane on particle size, PDI and ζ-potential (n = 3). 
 
The particle sizes prior to re-probing were greater than those observed in Section 2.3.1 
probably due to instability of the liposomes upon storage. Re-probing significantly reduced 
the particle size of both DPPC and DSPC liposomes (Tables 2.2a and 2.2b) to a range 
suitable for drug delivery across the BBB (< 100 nm) [43]. Again, particle sizes increased 
with o-carborane loading and all sizes were larger for DSPC liposomes compared with 
those of DPPC, due to the larger lipid chain length of the former. PDI values for all 
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liposomes were again < 0.5 indicative of very evenly monodispersed and homogenous 
particle size distributions. Values of between -30 and +30 mV were again observed for the 
ζ-potentials, suggesting agglomeration may result. 
 
Table 2.2a. Effect of re-probing DPPC liposomes containing various loadings of o-
carborane on particle size, PDI and ζ-potential (n = 3).  
Vol. of o-carborane / µL 1000 500 250 25 12.5 0 
n Probe        
1 Before d / nm 547.9 234.6 99.3 56.7 56.2 55.7 
PDI 1.000 0.608 0.318 0.204 0.352 0.242 
1 After d / nm 69.0 65.9 60.5 58.8 58.5 57.1 
PDI 0.105 0.116 0.48 0.155 0.266 0.273 
ζ / mV -0.365 -2.24 -1.04 -0.416 1.53 -1.39 
2 Before d / nm 114.5 106.9 88.74 85.04 65.35 61.75 
PDI 0.479 0.544 0.245 0.341 0.233 0.243 
2 After d / nm 81.5 80.6 70.1 64.8 63.0 60. 7 
PDI 0.357 0.413 0.168 0.199 0.115 0.259 
ζ / mV -4.31 -16.3 -16.5 -24.5 -35.2 -28.2 
3 Before d / nm 1046.0 136.4 99.9 89.2 78.6 74.3 
PDI 1.000 0.445 0.442 0.256 0.251 0.311 
3 After d / nm 75.5 50.2 44.1 43.5 42. 6 42.1 
PDI 0.171 0.243 0.3000 0.260 0.222 0.239 
ζ / mV -2.52 -13.5 -13.1 -22.9 -20.8 -20.4 
Mean 
± SD 
After d / nm 75.3±6.2 65.6±15.2 58.2±13.2 55.7±11.0 54.7±10.7 53.3±9.9 
PDI 0.21±0.13 0.26±0.15 0.32±0.16 0.21±0.05 0.20±0.08 0.26±0.02 
ζ / mV -2.40±1.98 -10.68±7.44 -10.21±8.12 -15.94±13.47 -18.16±18.51 -16.66±13.79 
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Table 2.2b. Effect of re-probing DSPC liposomes containing various loadings of o-
carborane on particle size, PDI and ζ-potential (n = 3).  
Vol. of o-carborane / µL 1000 500 250 25 12.5 0 
n Probe        
1 Before d / nm 150.5 146.9 145.1 94.7 93.2 82.8 
PDI 0.280 0.217 0.179 0.136 0.177 0.215 
1 After d / nm 111.0 105.8 96.51 93.5 82.7 59.5 
PDI 0.167 0.220 0.180 0.169 0.159 0.262 
ζ / mV -3.92 -5.46 -11.8 -23.7 -20.2 -7.88 
2 Before d / nm 150.8 136.9 132.9 91.0 81.7 79.0 
PDI 0.220 0.131 0.186 0.092 0.135 0.176 
2 After d / nm 98.3 97.3 96.3 90.1 76.7 71.3 
PDI 0.186 0.204 0.160 0.143 0.098 0.134 
ζ / mV -4.37 -12.4 -17.4 -3.21 -31.5 -22.3 
3 Before d / nm 588.4 130.3 79.7 73.0 86.9 80.5 
PDI 0.956 0.487 0.215 0.163 0.212 0.186 
3 After d / nm 85.8 81.4 64. 3 39.3 39.0 38.8 
PDI 0.209 0.285 0.249 0.307 0.304 0.246 
ζ / mV -2.06 -16.0 -17.9 -2.99 -26.8 -21.0 
Mean 
± SD 
After d / nm 98.4±12.6 94.9±12.4 85.7±18.5 74.3±30.4 66.1±23.7 56.6± 6.5 
PDI 0.19±0.02 0.24±0.04 0.20±0.05 0.21±0.01 0.19±0.11 0.21±0.07 
ζ / mV -3.45±1.22 -11.30±5.36 -15.7±3.39 -9.97±11.89 -26.12±5.68 -17.06±7.98 
 
2.3.3 Stability of liposome properties after one week 
Since the ζ-potentials of the liposomes suggested that agglomeration may be an important 
factor, the particle sizes were re-measured after 1 week of storage in the fridge (3-5 °C). 
Liposomes were probed once before storage but not re-probed after the storage period. 
Particle sizes and PDI values of DPPC and DSPC liposomes are shown in Tables 2.3a and 
2.3b, respectively. 
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Before particles were left in storage, particle size measurements indicated that increased o-
carborane incorporation increased particle sizes for both DPPC and DSPC liposomes. At 
lower concentrations, the particles sizes were within the 100 nm acceptable range. For 
DSPC liposomes, particle sizes increased to very high values with increasing volumes of o-
carborane. PDI values were generally < 0.5, reflecting high monodispersity and 
homogeneity, although some DSPC liposomes at higher o-carborane incorporations 
slightly exceeded this limit. After storage, liposome sizes generally increased although to 
no observable pattern and not obviously related to o-carborane content. The liposomes 
were not re-probed, although this would probably have reduced the particle sizes to values 
< the required 100 nm. This is investigated in the next section. 
 
Table 2.3a. Mean particle sizes and PDI values of DPPC liposomes before and after 
storage at 3-5 °C for 1 week; n = 3; SD = standard deviation. 
Volume of 
o-carborane  
/ µL 
Before After 
 d / nm PDI d / nm PDI 
1000 262.0 ± 191.8 0.44 ± 0.33 394.9 ± 385.2 0.71 ± 0.30 
500 139.3 ± 37.6 0.41 ± 0.12 170.4 ± 62.5 0.31 ± 0.10 
250 100.7 ± 18.4 0.21 ± 0.06 120.2 ± 26.1 0.35 ± 0.20 
25 86.3 ± 4.6 0.26 ± 0.22 93.7 ± 4.8 0.19 ± 0.08 
12.5 83.4 ± 5.5 0.24 ± 0.02 106.1 ± 15.1 0.16 ± 0.01 
0 61.0 ± 19.5 0.30 ± 0.18 113.3 ± 28.8 0.43 ± 0.32 
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Table 2.3b. Mean particle sizes and PDI values of DSPC liposomes before and after 
storage at 3-5 °C for 1 week; n = 3; SD = standard deviation. 
Volume of 
o-carborane  
/ µL 
Before After 
 d / nm PDI d / nm PDI 
1000 3917.2 ± 3614.7 0.46 ± 0.16 2225.4 ± 1839.2 0.51 ± 0.44 
500 2335.6 ± 2707.4 0.57 ± 0.44 3062.1 ± 3838.5 0.57 ± 0.43 
250 1802.1 ± 2347.4 0.61 ± 0.45 287.2 ± 187.7 0.42 ± 0.22 
25 245.0 ± 165.6 0.52 ± 0.35 95.7 ± 4.4 0.23 ± 0.13 
12.5 82.3 ± 5.5 0.09 ± 0.02 93.1 ± 4.8 0.27 ± 0.07 
0 76.0 ± 2.6 0.15 ± 0.13 900.4 ± 698.1 0.74 ± 0.45 
 
2.3.4 AFM 
AFM was used to investigate the stability of liposomes containing o-carborane over longer 
periods than one week. In these studies, the liposomes were re-probed prior to measuring 
sizes with the AFM. This technique also has the advantages of observing the morphology 
of the liposomes and checking for agglomeration. Line profiles were used to obtain the 
particle sizes from the AFM images. Diameter (d) and height (h) values were obtained to 
check which property was more appropriate for the particle size measurements. This is 
because diameter measurements are known to be influenced by broadening artefacts 
caused by the larger AFM tip moving across a smaller sample (Figure 2.5). Images of 
DPPC and DSPC liposomes without and with o-carborane (maximum volume, 1000 µL) 
obtained after 1, 19, 35, 49 and 63 days after preparation are shown in Figures 2.6 – 2.9. 
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Figure 2.5. Origin of AFM tip broadening artefact. The red line shows a 2D view of the 
artefact with corresponding oversized diameter measurement (d); the true diameter (height, 
h) is shown. The yellow arrow shows the scan direction. 
 
The unloaded liposomes, both DPPC and DSPC, often appeared as agglomerated 
islands/rafts, probably composed of lipid bilayers, with attached isolated spherical 
liposomes (Figure 2.10). These islands were largely unseen for the loaded liposomes. This 
may be due to poor sampling technique or some increased stability of the loaded liposomes 
resulting from more hydrophobic interactions between o-carborane and the hydrophobic 
lipid tails (Figure 2.11).  
 
In terms of particle size, loaded liposomes, both DPPC and DSPC, were generally larger 
than their unloaded counterparts (Tables 2.4 and 2.5) as observed in previous 
measurements (Section 2.3.1). 
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(a)    (b)    (c) 
 
(d)    (e) 
Figure 2.6. Representative AFM images of unloaded DPPC liposomes obtained after 1, 19, 
35, 49 and 63 days (a – e, respectively; n=4). 
 
This pattern was reflected in both diameter and height AFM measurements, although the 
former were much larger due to the expected tip broadening effect (Figure 2.5). 
Interestingly, the AFM height measurements gave appreciably (an order of magnitude) 
lower values than diameters obtained from the zeta sizer. This suggests that the AFM 
determined diameters may not be as affected by the tip broadening artefact as first thought, 
possibly due to the tip being sharp. The low height values may be due to compression of 
the liposomes by the AFM tip. 
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(a)    (b)    (c) 
 
(d)    (e) 
Figure 2.7. Representative AFM images of o-carborane loaded DPPC liposomes obtained 
after 1, 19, 35, 49 and 63 days (a – e, respectively; n=4). 
 
The loaded liposomes generally appeared intact after 63 days of storage suggesting a 
successful formulation had been achieved. The fact that the liposomes needed re-probing 
to produce particles in the correct size range is not a limitation, since the product would be 
stored in a laboratory fridge before administering it to the patient. In other words, it is not 
like a commercial drug where long term stability outside of a laboratory environment 
needs to be demonstrated.  
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(a)    (b)    (c) 
 
(d)    (e) 
Figure 2.8. Representative AFM images of unloaded DSPC liposomes obtained after 1, 19, 
35, 49 and 63 days (a – e, respectively; n=4). 
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(a)    (b)    (c) 
 
(d)    (e) 
Figure 2.9. Representative AFM images of o-carborane loaded DSPC liposomes obtained 
after 1, 19, 35, 49 and 63 days (a – e, respectively; n=4). 
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Table 2.4. Time variation of particle sizes (diameters) of DPPC and DSPC liposomes 
unloaded and loaded with o-carborane (1000 µL) determined using AFM.  
 Mean d / nm 
Time / days DPPC 
Unloaded 
DPPC 
Loaded 
DSPC 
Unloaded 
DSPC 
Loaded 
1 86.4 ± 24.8 121.4 ± 26.7 83.3 ± 20.6 130.9 ± 26.2 
19 89.0 ± 37.2 103.2 ± 20.4 87.0 ± 24.0 108.3 ± 21.5 
35 83.6 ± 22.1 101.0 ± 28.0 66.5 ± 16.2 108.7 ± 22.6 
49 85.7 ± 21.4 62.0 ± 22.7 58.5 ± 15.4 89.4 ± 20.4 
63 77.4 ± 25.2 35.3 ± 11.2 100.0 ± 36.2 113.0 ± 22.2 
 
 
Table 2.5. Time variation of particle sizes (heights) of DPPC and DSPC liposomes 
unloaded and loaded with o-carborane (1000 µL) determined using AFM.  
 Mean h / nm 
Time / days DPPC 
Unloaded 
DPPC 
Loaded 
DSPC 
Unloaded 
DSPC 
Loaded 
1 9.3 ± 2.7 16.8 ± 4.91 6.8 ± 2.1 19.9 ± 4.3 
19 11.4 ± 7.02 14.0 ± 3.4 8.1 ± 3.5 18.6 ± 5.3 
35 13.1 ± 5.7 7.8 ± 3.7 8.6 ± 3.7 20.6 ± 4.0 
49 11.6 ± 4.5 4.8 ± 0.31 9.2 ± 3.9 21.3 ± 6.4 
63 8.2 ± 3.1 4.5 ± 1.1 7.4 ± 2.2 18.3 ± 5.1 
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Figure 2.10. Breakdown of liposomes to form lipid bilayer islands/rafts on mica.  
 
 
(a)      (b) 
Figure 2.11. Liposomes (a) unloaded and (b) loaded with o-carborane. The latter structure 
may be more stable due to increased non-polar interactions and so might be less 
susceptible to collapse to form lipid bilayer islands/rafts.   
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2.3.5 SEM 
To further investigate liposome morphology and to compare particle sizing data obtaining 
via the zeta sizer and AFM, SEM images were obtained (Figure 2.12) and particle 
diameters measured (Figure 2.13). The unloaded and o-carborane loaded (1000 µL) 
liposomes were mainly spherical and featureless, with the loaded structures again 
appearing to be larger than the unloaded liposomes. This was confirmed by measuring the 
diameters of these structures (Figure 2.13). 
 
   
(a)    (b)    (c) 
   
(d)    (e)    (f) 
Figure 2.12 SEM images of unloaded (a,b,c) and o-carborane (1000 µL) loaded (d,e,f) 
DSPC liposomes on mica. 
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Other studies have shown that o-carborane loaded 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) liposomes were also larger than their unloaded counterparts [43]. 
Sizes were in the range measured using laser diffraction methods (Malvern Nanosizer, 
Sections 2.3.1-2.3.3). This supports the theory that particle sizes obtained via AFM height 
measurements were subject to compression and the tip-broadening artefact was not a major 
limitation (Section 2.3.4); AFM diameter, rather than height, measurements were therefore 
concluded to be satisfactory for obtaining particle size data. 
 
 
Figure 2.13. Mean particle sizes of unloaded and o-carborane loaded DSPC liposomes 
obtained from SEM images (3 images, n = 10); error bars = SD. 
 
2.3.6 Stabilisation of liposomes with cholesterol and serum 
To assess the stability of the liposome formulations in physiologically-relevant media, the 
leaching of the water-soluble, hydrophilic fluorescent marker calcein from these vehicles 
206 
191 
205 
328 
275 
197 
0
50
100
150
200
250
300
350
400
450
Unloaded 1 Unloaded 2 Unloaded 3 Loaded 1 Loaded 2 Loaded 3
M
e
an
 p
ar
ti
cl
e
 s
iz
e
 /
 n
m
 
Liposomes and image number 
Chapter 2: Liposomes loaded with o-carborane for BBB delivery 
92 
 
was investigated. To improve the stability of DPPC and DSPC liposomes, the effect of 
cholesterol inclusions were investigated. Cholesterol is known to stabilise liposome 
formations by increasing rigidity and preventing leakage [44]. These studies were carried 
out by following the release of calcein from the liposomes after treatment with Triton X-
100, which disrupts the lipid bilayers. DPPC and DSPC liposomes containing calcein were 
first prepared as described previously (Sections 2.2.1.6 and 2.2.2) and particle sizes, PDI 
values and -potentials obtained in PBS medium and in rat serum (37 °C) (Table 2.6). 
Statistical differences in particle diameters (Figure 2.14) are summarised in Table 2.7. 
 
Table 2.6. Particle size, PDI and ζ-potential values for DPPC and DSPC liposomes 
incorporating calcein, with and without cholesterol in PBS and serum (n=3). 
 Mean ± SD 
Liposomes + 
Calceina 
 
d / nm PDI ζ / mV 
DPPC 42.0 ± 5.2 0.31 ± 0.33 -4.62 ± 0.62 
DPPC+S 64.4 ± 3.1 0.32 ± 0.10 -2.84 ± 1.14 
DPPC+C 68.2 ± 5.7 0.37 ± 0.13 -2.70 ± 3.34 
DPPC+C+S 98.8 ± 1.0 0.40 ± 0.30 -4.76 ± 6.42 
DSPC  58.6 ± 5.8 0.29 ± 0.20 -3.80 ± 4.01 
DSPC+S 76.4 ± 2.6 0.38 ± 0.13 -3.30 ± 3.12 
DSPC+C 81.5 ± 8.6 0.28 ± 0.13 -3.55 ± 3.11 
DSPC+C+S 99.8 ± 1. 6 0.33 ± 0.16 1.50 ± 5.58 
a
 S = serum (PBS when S not stated); C = cholesterol. 
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DSPC liposomes were larger than DPPC liposomes in all cases (p < 0.05), as observed 
previously, due to the longer chain-length of the former lipid. For both types of liposomes, 
in the absence of cholesterol, particle diameters were larger in serum than in PSB buffer; 
the liposomes in serum were larger still when the particles incorporated cholesterol. The 
latter observation was expected since cholesterol is known to interface between the lipid 
bilayers, increasing their stability and hence increasing their size.  
 
Figure 2.14. Particle size variation for different formulations of DPPC and DSPC 
liposomes incorporating calcein, with and without cholesterol in PBS and serum (error bar 
= SD; n = 3). 
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Table 2.7. Statistical differences (p values) between particle sizes for DPPC and DSPC 
liposomes incorporating calcein, with and without cholesterol in PBS and serum (one-way 
ANOVA, post-hoc analysis). 
 DPPC DPPC+S DPPC+C DPPC+C+S DSPC DSPC+S DSPC+C DSPC+C+S 
DPPC  0.001 0.000 0.000 0.012 0.000 0.000 0.000 
DPPC+S   0.974 0.000 0.820 0.109 0.009 0.000 
DPPC+C    0.000 0.298 0.469 0.058 0.000 
DPPC+C+S     0.000 0.001 0.009 1.000 
DSPC      0.007 0.001 0.000 
DSPC+S       0.884 0.000 
DSPC+C        0.005 
DSPC+C+S         
 
Figure 2.15a and b and Figure 2.16a and b show the stability of the DPPC and DSPC 
liposomes in terms of %latency and %retention over a 24 h period in PBS (pH 7.4), with 
and without the presence of cholesterol. Latency refers to the amount of encapsulated 
calcein (hydrophilic marker) within the DPPC/DSPC liposomes at a given time (Equation 
2.4), whereas retention refers to the amount of calcein left after the liposomes have been 
dispersed in Triton X-100 to leach out the calcein (Equation 2.5). Both parameters provide 
a measure of the membrane integrity. 
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Figure 2.15a. Latency of DPPC liposomal dispersions formulated with and without 
cholesterol in PBS and serum. Formulations were incubated at 37 °C. Data are presented as 
mean ± SD (n=3). 
 
Figure 2.15b. Retention of DPPC liposomal dispersions formulated with and without 
cholesterol in PBS and serum. Formulations were incubated at 37 °C. Data are presented as 
mean ± SD (n=3). 
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Figure 2.16a. Latency of DSPC liposomal dispersions formulated with and without 
cholesterol in PBS and serum. Formulations were incubated at 37 °C. Data are presented as 
mean ± SD (n=3). 
Figure 2.16b. Retention of DSPC liposomal dispersions formulated with and without 
cholesterol in PBS and serum. Formulations were incubated at 37 °C. Data are presented as 
mean ± SD (n=3). 
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For DSPC liposomes in PBS media, the %latency was almost always higher when 
vessicles had been prepared with cholesterol rather than without (Figure 2.15a). This was 
expected oweing to the known influence of cholesterol to increase DSPC liposome stability 
[39,45,46]. Cholesterol also increased the capacity of the vehicles to accommodate calcein 
(Figure 2.15b). Consistent with literature reports, the latency of DSPC/cholesterol 
liposomes was higher than their DPPC/cholesterol congeners [47]. For the DPPC 
liposomes, however, cholesterol slightly reduced liposome stability over most of the time 
points investigated (Figure 2.16a), although the calcein retention was greater with 
cholesterol (Figure 2.16b). 
 
For both DPPC and DSPC liposomes, without cholesterol, %latency was significantly 
reduced in serum compared with those in PBS media (Figures 2.15b and 2.16b). The 
inclusion of cholesterol, however, increased the %latency to levels similar to those in PBS 
media for DSPC lipsomes and for much above this in the case of DPPC liposomes (ca. 
100%; Figure 2.15b). Retention values for both DPPC and DSPC liposomes with 
cholesterol in serum were generally the highest. Thus, over a 24 h per period, the integrity 
of the lipid membrane for both types of cholesterol-containing liposomes in serum media 
was high when cholesterol was used in their preparation. 
 
2.3.7 Nile red experiments 
Nile red, another fluorescent marker, was incorporated into o-carborane loaded liposomes 
to displace the boron compound and thus offering a quantitative method for determining o-
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carborane entrapment. This would also provide information as to whether o-carborane was 
incorporated into the liposomes at a sufficient quantity to be useful for the BNCT process.  
 
DPPC and DSPC liposomes containing a fixed volume of Nile Red (1000 μL; 2.5 μM) and 
a range of o-carborane volumes (0, 12.5, 25, 250, 500 and 1000 μL) for entrapment were 
prepared (Section 2.2.1.6 and 2.2.1.7). The liposomes were characterised in terms of 
particle size, PDI and -potential as previously performed (Section 2.3.1; Table 2.8). 
 
Table 2.8. Particle size, PDI and ζ-potential values for DPPC and DSPC liposomes 
incorporating Nile Red and differing volumes of o-carborane (n=2). 
 DPPC, Mean ± SD DSPC, Mean ± SD 
Liposomes 
+ o-carborane  
/ µL 
d / nm PDI ζ / mV d / nm PDI ζ / mV 
0 63.3 ± 28.9    0.20 ± 0.02 0.02 ± 0.83 71.9 ± 11.7 0.38 ± 0.00 -4.55 ± 4.55 
12.5 65.8  ± 31.2    0.31 ± 0.09 -0.21 ± 0.91 74.9 ± 15.3 0.29 ± 0.14 -3.81 ± 5.00 
25 67.5 ± 29.4   0.21 ± 0.04 -1.71 ± 0.95 77.2 ± 16.0 0.41 ± 0.04 0.38 ± 0.33 
250 73.8 ± 28.1 0.26 ± 0.09 -13.33 ± 10.14 88.9 ± 11.5 0.41 ± 0.08 -20.00 ± 4.53 
500 82.6 ± 24.5    0.16 ± 0.01 -14.78 ± 10.77 97.7 ± 19.0 0.29 ± 0.19 -12.70 ± 17.39 
1000 87.6 ± 31.1 0.19 ± 0.01 -16.78 ± 9.65 100.7 ± 21.3 0.32 ± 0.05 -11.09 ± 15.29 
 
 
These results confirm that liposomes were again successfully produced and with the 
desired particle sizes required (< 100 nm). DPPC particles were smaller than DSPC 
liposomes and PDI and -potential values were also in agreement with those obtained 
previously (Section 2.3.1). Since the mean particle size increased with increasing o-
carborane volume, as observed previously, this suggests that increasingly higher volumes 
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of o-carborane used in the preparation were being encapsulated in the liposomes. The 
purpose of this experiment, of course, was to prove this was indeed the case by measuring 
the fluorescence intensity of the liposome formulations: entrapped Nile Red should occupy 
the remaining space in the liposomes not filled with o-carborane. In other words, higher 
fluorescence intensities should be recorded with samples than contained lower volumes of 
the entrapped boron compound. It was interesting to note that particle size increased with 
o-carborane volume though, since the void space should be filled with Nile Red solution 
and therefore similar particle sizes would have been expected independent of o-carborane 
volumes. 
 
Figures 2.17a and b show the variation of fluorescence intensity for DPPC and DSPC 
liposomes, respectively, containing Nile Red and differing volumes of o-carborane. As 
expected, the highest fluorescence intensities, for both DPPC and DSPC liposomes, were 
obtained with formulations containing no o-carborane and intensities decreased 
progressively with increasing volumes of this compound. These results semi-quantitatively 
suggest that the volume of o-carborane used to prepare the liposomes was successfully 
entrapped within these vesicles. To formally quantify o-carborane incorporation, the boron 
content was next determined from digested formulations using ICP-MS.    
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Figure 2.17a. Nile Red incorporation into DPPC liposomes loaded with different volumes 
of o-carborane. 
 
Figure 2.17b. Nile Red incorporation into DSPC liposomes loaded with different volumes 
of o-carborane. 
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2.3.8 ICP-MS measurements of o-carborane incorporation 
To quantitatively assess the volume of o-carborane entrapped within the DPPC and DSPC 
liposomes, formulations were digested with conc. H2SO4 / H2O2 (Section 2.2.5) and 
analysed using ICP-MS for boron content (Table 2.9; Figure 2.18). 
 
Table 2.9. ICP-MS detected volumes of o-carborane with different DPPC and DSPC 
liposome o-carborane inclusions (n=3). 
 Mean ICP-MS detected vol. o-carborane / µL 
Formulated vol. o-carborane / 
µL 
DPPC DSPC 
0 3.05 ± 1.05 3.66 ± 0.31 
12.5 12.34 ± 7.52 9.74 ± 1.41 
25 23.57 ± 9.56 25.83 ± 3.75 
250 207.83 ± 155.50 259.04 ± 16.28 
500 398.18 ± 165.81 524.67 ± 51.31 
1000 1021.57 ± 370.05 1271.63 ± 271.23 
 
 
The results show a clear match between the actually incorporated volumes of o-carborane 
with those actually determined. The gradients of the plots (Figure 2.18) were very close to 
1 (DPPC: 0.995; DSPC: 1.249). 
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Figure 2.18. Comparison of detected versus actually incorporated volumes of o-carborane 
into DPPC and DSPC liposomes using ICP-MS. 
 
2.4 Summary 
DPPC and DSPC SUV liposomes with particle diameters of ca. 80 – 100 nm containing o-
carborane were successfully produced using the thin film method. Those of DSPC had 
slightly larger particle sizes as reflected by their longer carbon chain. For both DPPC and 
DSPC liposomes, particle diameter increased with increasing entrapped o-carborane 
volumes. The liposomes had a monodispersed, homogeneous particle size distribution (PDI 
< 0.5), although possessed -potentials in a range indicative of instability (between -30 and 
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+30 mV). However, this was probably due to high ionic strength of the PBS medium and 
re-probing was found to reduce agglomerated particle to the required size range over 
storage at 3 – 5 °C for 1 week. AFM studies showed that the loaded liposomes generally 
appeared intact after 63 days of storage if re-probing was employed. The integrity of the 
liposome membrane in serum, as reflected by %latency and %retention experiments using 
a fluorescent marker (calcein), was found to be high for both DPPC and DPPC liposomes 
prepared using cholesterol. Co-entrapment of o-carborane with Nile Red into the liposomes 
semi-quantitatively confirmed the required volume of the boron compound successfully 
became entrapped with the liposomes. This was proven quantitatively using ICP-MS 
measurements. 
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Chapter 3 
Efficacy of specific formulations of o-carborane 
3.1 Introduction 
In Chapter 2, stable DPPC and DSPC SUV liposomes that incorporated o-carborane were 
successfully formulated and characterised. Since the focus was on the integrity and 
stability of the liposomes themselves, to keep costs to a minimum, a model, non-specific o-
carborane was used. In other words, this carborane is unable to target cancer cells that 
would be key for the BNCT approach. In this Chapter, however, since knowledge of the 
liposome formulation has been obtained, attention is now moved to targeting cancer cells 
with carborane derivatives. 
 
3.1.1 Targeting cancer cell mitochondria 
Mitochondria are organelles that are present in the majority of cells and are often described 
as the ‘power houses’ since they are the main source of adenosine triphosphate (ATP) 
needed for respiration (energy generation) [1,2]. They also play a key role in programmed 
cell death (apoptosis) (Figure 3.1) [3,4]. Each organelle consists of a matrix of extra-
chromosomal mitochondrial DNA (mtDNA) and enzymes surrounded by a double 
membrane (Figure 3.2) [5,6]. The outer membrane is permeable to small molecules 
(nucleotides, sugars and salts), whilst the inner, folded (into cristae) layer is selectively 
permeable, allowing passage of pyruvic acid and O2 into the organelle and removal of ATP 
and CO2 [6].    
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Figure 3.1. Schematic showing the extrinsic and intrinsic pathways of apoptosis. Adapted 
from [2]. 
 
Figure 3.2. Cross-sectional image of a single mitochondrion [5]. 
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At the mitochondria inner membrane (MIM; Figure 3.2), oxygen is reduced to water by the 
passage of electrons from NADH and succinate via an enzymatic series of electron donors 
and acceptors [7]. This produces a proton gradient across the MIM known as the 
mitochondria cell membrane potential (ΔΨm) [7,8]. This property conveniently provides a 
measure of the energetic condition of the mitochondria and the level of dysfunction [9-11]. 
For example, the ΔΨm of neoplastic cells are quite different from non-neoplastic cells [12]: 
-60 mV for neoplastic cells [13], and lower values being obtained from non-neoplastic 
cells, reflective of the damaged mitochondrial metabolic activities in cancer [10]. In 
addition, in-vitro ΔΨm values are also estimated to be  180-200 mV [14] compared to 130-
150 mV [15] for those measured in vivo. Brain mitochondria are regulated by ΔΨm [16] 
which plays an important  role in cancer metabolism (aerobic glycolysis), as proposed by 
Warburg in 1930 [3,10], which causes resistance to cell death. It is therefore an ideal select 
target for cancer therapy [3]. 
 
3.1.2 Mito dyes 
There are quite a number of mitochondrial dyes, some of which make use of the differing 
in vitro ΔΨm values between neoplastic and non-neoplastic cells to providing visual 
distinctions between these two cell populations (Figure 3.3) [17]. Many of these dyes are 
delocalised lipophilic cations (DLCs), i.e., they have an extended conjugated -electron 
system, are hydrophobic and bear a positive charge (via one or more nitrogen atoms) [18]; 
a few key examples are shown in Figure 3.3. Dequalinium chloride, a dication consisting 
of two quaternary quinolinium rings separated by a dodecylene chain (Figure 3.3a), 
exhibits some anticarcinoma activity, prolonging survival in mice [19]; it has also been 
used extensively as an antiseptic [20].  
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Figure 3.3. Chemical structures of some common DLCs: (a) dequalinium chloride, (b) 
rhodamine-123 chloride, (c) Nile Blue chloride, (d) Mitotracker Red CMXRos, (e) 
Mitoracker Green, and (f) JC-1. 
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Rhodamine-123 chloride is a green fluorescent dye that is used to visualise mitochondria 
and to estimate mitochondrial activity (Figure 3.3b) [18]. MitoTracker Green (MTG) also 
selectively accumulates in the mitochondria and is used in confocal microscopy and flow 
cytometry; the dye covalently binds to mitochondrial proteins via cysteine SH groups 
(Figure 3.3e) [21]. JC-1 is a novel cationic carbocyanine dye (Figure 3.3f), which exists as 
a monomer at low concentration and at higher concentrations, forms aggregates with a 
different emission maximum and hence can be a sensitive ΔΨm marker: mitochondria with 
high values of ΔΨm appear orange and low values appear green [22]. 
 
The selective accumulation of DLCs in the mitochondria is a direct consequence of the 
Nernst Equation (Equation 3.1): 
∆𝜓(𝑚𝑉) = 61.5 log10 {
[𝐷𝐿𝐶]𝑖𝑛
[𝐷𝐿𝐶]𝑜𝑢𝑡
}      (Equation 3.1) 
Hence, there will be a ten-fold increase in DLC species for every 61.5 mV increment in 
, and so there will be an increased concentration of DLC in cancer cells compared with 
normal cells [13,23].  
 
3.1.3 Use of carborane DLC derivatises for BNCT 
DLCs can be derivatised with boron-containing compounds to produce mitrochrondrial-
targetted BNCT agents [24-26]. They can either be through convalent attachment or using 
the ionic salt structure, replacing the chloride ion with a carborane anion. The latter 
approach has had some recent attention: dequalinium bis nido o-carborane salt (DC; Figure 
Chapter 3: Efficacy of specific formulations of o-carborane 
113 
 
3.4) was synthesised by Calabrese et al. [24], although technical difficulties in finding 
appropriate filter-sets to investigate the uptake of this compound by cells proved difficult. 
Specific targeting of cancer cells using an analogous rhodamine-123 bis nido o-carborane 
salt was successful however, with fluorescence being observed in prostate cancer (PC3) 
cell lines, but not in an equivalent non-neoplastic control (PNT2) [24].  
N
+
NH2
N
+
NH2
 
 
Figure 3.4. Chemical structure of dequalinium bis nido o-carborane salt (DC). 
 
3.1.4 Aims 
The aim of the work in this chapter was to synthesise DC and to assess its ability to 
selectively target the mitochondria of glioma (GMB) cells, whilst leaving non-neoplastic 
cells (astrocytes) intact. The cell lines investigated were IN699 (GMB, grade IV) and 
SC1800 (non-neoplastic astrocytes, a control), and were considered more appropriate for 
BNCT studies than the prostate cell lines used previously. DC has been synthesised before 
for use as a BNCT agent, although suitable fluorescence filter sets were not available for 
use with this compound [24]. Prior to treating cells, the cytotoxicity of DC was examined 
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using an MTS assay, since the agent itself should not be cytotoxic: cells should only be 
damaged once the compound has reached its target and the BNCT nuclear reaction 
initiated. 
 
An MTS assay is known as a one-step MTT assay, which is a colourimetric method of 
assessing cell viability:  enzymes in viable cells reduce colourless 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) to a purple-
coloured formazan product (490 – 500 nm), in the presence of phenazine methosulfate 
(PMS) in PBS buffer (Figure 3.5) [27]. Therefore dead cells will produce a less intensely 
coloured solution. 
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Figure 3.5. MTS assay: formation of coloured formazan derivative by viable cells. 
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3.2 Materials and methods 
3.2.1 Chemicals and instrumentation 
Dequalinium chloride was purchased from Sigma (Dorset, UK). o-Carborane was 
purchased from BOC Sciences (NY, USA). Potassium hydroxide pellets were purchased 
from Acros Organics (NJ, USA). Methanol, toluene and petroleum ether were obtained 
from Fisher Scientific (Loughborough, UK). Deuterated chloroform, deuterated methanol 
and tetramethylsilane (TMS) for NMR were purchased from Cambridge Isotope 
Laboratories, Inc. (USA). Silica gel filter plates for thin layer chromatography (TLC) (5 
cm  10 cm; silica gel 60 F254) were sourced from Merck (Darmstadt, Germany). 
 
1
H, 
13
C and 
11
B NMR spectra were obtained using a JEOL Eclipse+ 400 MHz NMR 
instrument (Peabody, USA), operating at a field strength of 9.389766 T. 
 
3.2.2 Synthesis of dequalinium bis nido o-carborane salt (DC) 
Synthesis of DC in the same quantities was carried out as described elsewhere [24]. TLC 
confirmed the reaction had gone to completion. 
TLC: Rf = 0.57 (DC), 0.20 (dequalinium chloride), 0 (o-carborane) (10:9:1 methanol : 
petroleum ether : toluene).  
 
1
H NMR (400 MHz, CD3OD):  8.31 (dd, J1 = 8.42 Hz, J2 = 1.10 Hz, 2H), 8.08 (d, J = 8.42 
Hz, 2H), 8.02 (dd, J1 = 8.06 Hz, J2 = 1.46 Hz, 2H), 7.68 (ddd, J1 = 7.51 Hz, J2 = 7.51 Hz, J3 
= 1.10 Hz, 2H), 6.75 (s, 2H), 4.49 (t, J = 8.42 Hz, 4H), 2.76 (m, 6H), 1.89–1.81 (m, 4H), 
1.67 (m, 4H), 1.53 (m, 4H), 1.41 (m, 8H-B); Lit. 
1
H NMR (400 MHz, CD3OD):  8.32 (dd, 
J1 = 8.42 Hz, J2 = 1.28 Hz, 2H), 8.08 (d, J = 8.79 Hz, 2H), 8.02 (dd, J1 = 6.87 Hz, J2 = 1.36 
Chapter 3: Efficacy of specific formulations of o-carborane 
116 
 
Hz, 2H), 7.69 (ddd, J1 = 8.42 Hz, J2 = 6.96 Hz, J3 = 1.28 Hz, 2H), 6.75 (s, 2H), 4.50 (t, J = 
8.28 Hz, 4H), 2.76 (m, 6H), 1.86–1.79 (m, 4H), 1.68 (m, 4H), 1.53 (m, 4H), 1.41 (m, 8H-
B) [24]. 
 
13
C NMR (100.5 MHz, CD3OD):  157.63 (2C), 155.16 (2C), 139.58 (2C), 134.48 (2C), 
126.04 (2C), 123.92 (2C), 118.02 (2C), 117.06 (2C), 104.23 (2C), 55.83 (2C), 29.14 (2C), 
28.93 (2C), 28.36 (2C), 26.20 (2C), 20.92 (2C); Lit. 
13
C NMR (100.5 MHz, CD3OD):  
158.40 (2C), 155.87 (2C), 140.31 (2C), 135.12 (2C), 126.73 (2C), 124.62 (2C), 118.68 
(2C), 117.77 (2C), 104.83 (2C), 44.56 (2C), 29.93 (2C), 29.68 (2C), 29.66 (2C), 29.03 
(2C), 26.91 (2C), 21.47 (2C) [24]. 
 
11
B NMR (128.2 MHz, CDCl3):  -4.06 (s, 1B), -9.32 (s, 1B), -10.60 (s,1B), 14.63 (s, 2B), 
-15.49 (s, 1B), -18.33 (s, 2B), -23.22 (s, 2B), -34.49 (s, 1B), -39.23 (s, 1B); Lit. 
11
B NMR 
(128.2 MHz, CDCl3):  -14.63 (s, 2B), -15.65 (s, 1B), -18.30 (s, 2B), -23.22 (s, 2B), -34.52 
(s, 1B), -39.23 (s, 1B) [24].  
 
3.2.3 Cell culture 
GBM IN699 cells were obtained from the Institute of Neurology, London, where they were 
derived from the supratentorial Glioblastoma cells from a 15-year-old treatment-naïve 
male [28]. They were grown within P75 flasks (Cellstar filter cap cell culture flask, 250 
mL, 75 cm
2; Greiner) in DMEM & glutamax (Dulbecco’s Modified Eagle’s Medium; 
Gibco Life Technologies) supplemented with 10% foetal bovine serum (FBS; Clonetics 
AGM SingleQuots kits). SC1800 astrocyte cells were obtained from ScienCell Research 
Laboratories (#1800), where they were isolated from the human cerebral cortex and frozen 
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at passage 1, prior to being packaged and distributed in vials (1  106 cells mL-1) [29]. 
Cells were grown in P25 flasks (Cellstar filter cap cell culture flask, 50 mL, 25 cm
2
; 
Greiner) in AGM2 media, consisting of Clonetics ABM astrocyte basal medium (Lonza), 
10% human serum (Sigma), 1% L-glutamate (Lonza), 0.1% ascorbic acid (Lonza), 0.1% 
gentamycin & antimycin (Lonza), 0.1% external growth factor (Lonza) and 0.25% insulin 
(Lonza). Flasks of cells were incubated (37 °C, 5% CO2), unless otherwise stated. 
 
Cells were removed from flasks by typsination (removing existing media and washing with 
HBSS (Hanks’ Balanced Salt Solution; Gibco Life Technologies)). They were then 
incubated in TrypLE Express (Gibco Life Technologies) for 5 – 10 min until they became 
detached. Cells were then quenched with growth media to form a suspension, which was 
then centrifuged (1000 rpm, 5 min; Boeco centrifuge C-28A; Boeckel & Co) to form a 
pellet. This was then resuspended in growth media to form a homogeneous cell suspension 
and transferred to flasks containing growth media. The incubated cells were allowed to 
grow and split once ca. 80% confluency was obtained.  
 
3.2.4 MTS assay 
IN699 and SC1800 cell lines were used for the MTS assay [30]. Cells were cultured and 
seeded in three 96 well plates, one for each of the three time points: 24, 48 and 72 h. Each 
well plate had 24 wells seeded with IN699 cells and 24 wells seeded with SC1800s. Wells 
were set out for different concentrations of DC and appropriate controls (no DC and no 
cells; Figure 3.6); experiments were made in triplicate. The concentration range chosen 
was from 0.01 to 1 mM. 
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Figure 3.6. Arrangement of a 96 well plate for an MTS assay. 
 
The dilutions were made from a stock solution which had a concentration of 1 mM. The 
quantities of stock and media solutions prepared were calculated as follows: since one well 
takes 100 μL, calculation was made for the amount of 1 mM stock solution and media for 
100 μL required. For a concentration of 0 mM (the control) for example, 100 μL of media 
was needed and 0 μL of the stock solution. For a concentration of 0.01 mM, 100 μL  0.01 
= 1 μL of the stock solution has to be mixed with 100 μL – 1 μL = 99 μL of media etc. The 
ratios of stock solution/ media are shown in Table 3.1. 
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Table 3.1. Dilutions used for MTS assay. 
 [DC 5] / mM  
 
Volume of stock solution  
[1 mM] / μL  
 
Volume of DMSO Media / 
μL  
 
0 0 100 
0.01 1 99 
0.1 10 90 
0.25 25 75 
0.5 50 50 
0.75 75 25 
1 100 0 
 = 261 µL = 439 µL 
 
The total amount of needed stock solution for the 6 dilutions was 266 μL (Table 3.1), but 
since the work was carried out in triplicates and as there were three plates, the amount of 
stock solution needed was 261 μL  3  3 = 2349 μL for each cell line. The stock solutions 
and also the dilutions were prepared for each cell line separately since the cells required 
different media. The same calculation procedure was used for the media: 439 μL  3  3 = 
3951 μL for each cell line. 
  
Since the media and the stock solution were on an open bench and the drug treatment took 
place in the hood where it is worked under sterile conditions, it was decided to have more 
stock solution and media prepared than was required to allow for filtering of the solution 
(and hence loss of material). Stock solution (5 mL) and media (10 mL) were prepared for 
each cell line. 
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For 5 mL of stock solution (1 mM), the quantity of DC required was: 
 
𝑚 =  
𝐶𝑜𝑛𝑐  × 𝑉𝑜𝑙  × 𝑀𝑊
1000
= 3.617 𝑚𝑔      (Equation 3.2) 
 
This mass of DC (723.49436 g mol
-1
) was dissolved in media (5 mL), which consisted of 
media (4.95 mL, 1% DMSO) and DMSO (0.05 mL, to achieve improved DC solubility). 
An additional aliquot of DMSO (150 µL) was added to improve solubility, and so the total 
stock volume was 5.15 mL containing 3.88% DMSO. To check the concentration value of 
the stock solution (C), which might have changed from 1 mM, a re-calculation was made:  
 
𝐶 =  
𝑛
𝑉
          (Equation 3.3) 
where n = number of moles of DC and V = volume of solution (0.00515 L), and 
 
𝑛 =  
𝑚
𝑀𝑊
= 5.0 × 10−6 𝑚𝑜𝑙       (Equation 3.4) 
 
and therefore 
𝐶 =  
5.0 × 10−6
0.00515
= 9.7 × 10−4 𝑚𝑜𝑙 𝐿−1 = 0.97 𝑚𝑀 ≈ 1 𝑚𝑀  (Equation 3.5) 
Therefore, the concentration after adding additional DMSO was still ca. 1 mM.  
 
For the 10 mL of media + DMSO solutions, DMSO (0.1 mL) were mixed with media (9.9 
mL) to achieve a DMSO content of 1%. To achieve the same DMSO% as in the stock 
solutions, DMSO (300 μL) were added. The media + DMSO solutions then had 3.88% of 
DMSO. 
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After all stock solutions and media + DMSO solutions had been prepared, they were 
placed in a water bath (37 °C, 15 min). The hood was then prepared and all solutions were 
filtered with a syringe filter to obtain sterility. The six dilutions were then prepared: 1 mL 
per concentration, for each cell line in the Eppendorf tubes. The 96 well plates were then 
retrieved from the incubator, all media was removed from the wells and then the dilution / 
stock solution/ media + DMSO (100 μL) were pipetted into the respective wells. The well 
plate was labelled from the outside (so as not to forget which well had been pipetted with 
which concentration) and put back into the incubator.  
 
For the first time point (24 h), after 21.5 h had elapsed, one Eppendorf tube containing 
MTS solution was removed from the freezer and allowed to defrost for 30 min in the open 
lab (MTS solution was transferred previously from the original bottle into Eppendorf tubes 
and wrapped in tin foil, since MTS solution is light sensitive!). After 30 min, the MTS 
solution (yellow) was vortexed. Then the first 96 well plate was removed from the 
incubator, MTS solution (10 µL) was pipetted into each well which contained media (ratio 
1 : 10 → 10 μL MTS solution : 100 μL media), the plate was closed and wrapped with 
tinfoil and put in the incubator at 37 °C for a further 2 h. During this time, the MTS (a 
yellow tetrazole) was reduced to purple formazan, a natural process in living cells [31]. 
After the 2 h, the well plate was put into the plate reader and absorbance values obtained 
(490 nm). The received data is displayed as an Excel data file that was saved for 
subsequent data analysis. The same procedure was repeated with the remaining two plates 
for the second (48 h) and the third (72 h) time points. 
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3.2.5 Microscopy 
IN699 and SC1800 cell lines were grown in a 24 well plate, as described previously 
(Section 3.2.3). Aliquots containing various concentrations of DC (0, 0.1, 0.001 and 
0.0001 mM) in cell-specific media (for IN699 and for SC1800) were added to the cells (in 
triplicate), i.e., to obtain IN699 + DC (0, 0.01, 0.001, 0.0001 mM; n = 3) and SC1800 + 
DC (same concentrations; n = 3). 
 
Live cell imaging was performed using a Zeiss Axiovert 200M (inverted) microscope (Carl 
Zeiss, Welwyn Garden City, Herts, UK) contained in an incubator (37 °C, 5% CO2, humid 
atmosphere). A 10 objective was used and bright field images and fluorescence (filter set 
no. 10 ‘FITC’; Zeiss) were consecutively acquired every 15 min for 6 h (V5.4, Perkin 
Elmer). Maximum dye penetration before the onset of photobleaching occurred at 3.5 h. 
Images were obtained and overlayed using Volocity software (V6.1.1, Perkin Elmer). In 
addition, fluorescence imaging (20 and 40) of the DC crystals were also carried out 
using a variety of filter sets (no. 10 ‘FITC’, exc. 450 – 490 nm, em. 515 – 565 nm; 37 
‘GFP’, exc. 450/50 nm, em. 510/50 nm; 20 ‘Rhodamine’, exc. 546/12 nm, em. 575 – 640 
nm; and 00 ‘Texas Red’, exc. 530 – 585 nm, em. 615 nm; Zeiss). 
  
Chapter 3: Efficacy of specific formulations of o-carborane 
123 
 
3.3 Results and discussion 
3.3.1 Fluorescence imaging of DC 
Bright field and fluorescence images of DC crystals are shown in Figure 3.7. 
  
(a)      (b) 
   
(c)      (d) 
  
(e)      (f) 
Figure 3.7 (a). Bright field and (b-f) fluorescence images of DC crystals. Filter sets: (b) 20 
‘Rhodamine’, (c) 00 ‘Texas Red’, (d) 37 ‘GFP’, (e,f) 10 ‘FITC’. Bar = 60 µm (120 in f). 
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An intense fluorescence signal was displayed over a range of wavelengths for DC (Figure 
3.7), despite this not being observed in previous studies [24]. The reason why this was not 
observed in previous studies is unclear. The very intense fluorescent signals for the solid 
material showed promise for subsequent in vitro studies where diluted DC solution would 
be employed. 
 
3.3.2 MTS assay 
Absorbance values from the MTS assay after 24, 48 and 72 h are shown in Tables 3.2, 3.3 
and 3.4, respectively, for both IN699 and SC1800 cell lines. The %Viability is calculated 
as (Equation 3.6): 
 
%𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝐴𝑐
𝐴0
 × 100%       (Equation 3.6) 
 
where Ac = absorbance at DC concentration c (3 runs in triplicate  n = 9), and A0 = 
absorbance at of media in the absence of DC. 
 
%Viability plots vs. DC concentrations were then obtained (Figures 3.8 – 3.10) in order to 
calculate the LC50 values (Table 3.5), which is the concentration at which 50% of the cells 
are viable (acquired by interpolation). 
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SDs were calculated using Equations 3.7 – 3.8:  
𝑉𝑐  ± 𝑣𝑐 =  
𝐴𝑐 ± 𝑎𝑐 
𝐴0 ± 𝑎0
        (Equation 3.7) 
where Vc = viability expressed as a fraction (not %) for DC concentration c, vc = SD in 
viability for DC concentration c, Ac = mean absorbance for DC concentration c, ac = SD of 
absorbance for DC concentration c, A0 = mean absorbance for no DC, and a0 = SD of 
absorbance for no DC, and therefore vc can be calculated as: 
𝑣𝑐
𝑉𝑐
=  √(
𝑎𝑐
𝐴𝑐
)
2
+ (
𝑎0
𝐴0
)
2
        (Equation 3.8) 
 
The LC50 values (Table 3.5) were greater for the IN699 cell line compared with the 
SC1800s for all the 3 time points tested (24, 48 and 72 h). This is probably due to the 
inherent resistance of cancer cells to cytotoxic agents (DC, as with many chemicals, will 
become cytotoxic at some concentration). The reason for recovery in viability for both cell 
lines grown at 48 and 72 h is uncertain but may be due to layered cell growth in a media in 
which DC is poorly soluble. Importantly, however, the LC50 values are much higher, in the 
mM range, than the concentrations required for BNCT (and tumour concentration of 20 μg 
10B g-1 (per gram of tumour) [32]) and therefore DC will not be toxic to these types of 
cells. It is the BNCT nuclear reaction that is required to generate species ( particles) that 
destroy the cells (preferentially the cancer cells). 
 
  
Chapter 3: Efficacy of specific formulations of o-carborane 
126 
 
Table 3.2a. MTS data obtained for IN699 cell line after 24 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 
0.373 0.547 0.314 0.180 0.199 0.186 0.499 
RUN 1  
n = 2 
0.370 0.493 0.300 0.215 0.236 0.200 0.561 
RUN 1  
n = 3 
0.375 0.257 0.328 0.212 0.273 0.094 0.506 
RUN 2 
n = 1 
0.406 0.571 0.315 0.185 0.207 0.210 0.519 
RUN 2 
n = 2 
0.374 0.513 0.319 0.226 0.234 0.181 0.590 
RUN 2 
n = 3 
0.373 0.285 0.336 0.213 0.260 0.095 0.545 
RUN 3 
n = 1 
0.433 0.585 0.333 0.198 0.219 0.225 0.548 
RUN 3 
n = 2 
0.395 0.541 0.330 0.233 0.239 0.190 0.598 
RUN 3 
n = 3 
0.391 0.297 0.355 0.191 0.272 0.101 0.569 
Mean 0.388 0.454 0.326 0.206 0.238 0.164 0.548 
SD 0.021 0.134 0.016 0.018 0.027 0.053 0.035 
%Viability 70.73 82.87 59.39 37.55 43.33 30.00 100.00 
%SD 5.93 25.03 4.78 4.12 5.63 9.80 9.07 
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Table 3.2b. MTS data obtained for SC1800 cell line after 24 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 
0.395 0.368 0.190 0.115 0.102 0.114 0.434 
RUN 1  
n = 2 
0.286 0.198 0.165 0.080 0.082 0.091 0.479 
RUN 1  
n = 3 
0.501 0.169 0.173 0.086 0.081 0.163 0.316 
RUN 2 
n = 1 
0.379 0.340 0.236 0.112 0.099 0.124 0.473 
RUN 2 
n = 2 
0.302 0.195 0.128 0.074 0.088 0.095 0.413 
RUN 2 
n = 3 
0.421 0.152 0.176 0.090 0.083 0.168 0.324 
RUN 3 
n = 1 
0.379 0.338 0.235 0.106 0.099 0.118 0.489 
RUN 3 
n = 2 
0.304 0.207 0.122 0.072 0.087 0.090 0.437 
RUN 3 
n = 3 
0.434 0.180 0.191 0.094 0.082 0.175 0.360 
Mean 0.378 0.238 0.179 0.092 0.089 0.126 0.414 
SD 0.071 0.085 0.040 0.016 0.008 0.034 0.066 
%Viability 91.29 57.61 43.34 22.30 21.53 30.52 100.00 
%SD 22.50 22.44 11.88 5.25 3.98 9.53 22.59 
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Table 3.3a. MTS data obtained for IN699 cell line after 48 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 0.295 0.308 0.067 -0.045 0.042 0.516 0.281 
RUN 1  
n = 2 0.294 0.213 0.080 -0.093 -0.048 -0.056 0.185 
RUN 1  
n = 3 0.323 0.381 0.079 0.020 0.043 0.046 0.230 
RUN 2 
n = 1 0.300 0.332 0.051 -0.033 0.056 0.515 0.286 
RUN 2 
n = 2 0.294 0.205 0.107 -0.089 -0.025 -0.042 0.184 
RUN 2 
n = 3 0.317 0.389 0.087 0.043 0.049 0.026 0.239 
RUN 3 
n = 1 0.312 0.106 -0.029 0.053 0.088 0.117 0.335 
RUN 3 
n = 2 0.223 0.198 -0.006 0.086 0.104 0.128 0.362 
RUN 3 
n = 3 0.247 0.166 0.039 0.061 0.087 0.089 0.329 
Mean 0.289 0.255 0.053 0.000 0.044 0.149 0.270 
SD 0.033 0.100 0.045 0.067 0.051 0.217 0.065 
%Viability 107.19 94.55 19.53 0.15 16.27 55.12 100.00 
%SD 28.57 43.57 17.26 24.73 19.25 81.51 34.03 
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Table 3.3b. MTS data obtained for SC1800 cell line after 48 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 0.311 0.125 -0.031 0.037 0.078 0.115 0.403 
RUN 1  
n = 2 0.346 0.210 -0.013 0.078 0.089 0.112 0.424 
RUN 1  
n = 3 0.324 0.220 0.036 0.053 0.080 0.097 0.375 
RUN 2 
n = 1 0.321 0.113 -0.024 0.057 0.090 0.127 0.356 
RUN 2 
n = 2 0.248 0.195 0.001 0.083 0.101 0.125 0.359 
RUN 2 
n = 3 0.255 0.174 0.042 0.066 0.086 0.099 0.323 
RUN 3 
n = 1 0.312 0.106 -0.029 0.053 0.088 0.117 0.335 
RUN 3 
n = 2 0.223 0.198 -0.006 0.086 0.104 0.128 0.362 
RUN 3 
n = 3 0.247 0.166 0.039 0.061 0.087 0.089 0.329 
Mean 0.287 0.167 0.002 0.064 0.089 0.112 0.363 
SD 0.044 0.043 0.030 0.016 0.009 0.014 0.034 
%Viability 79.25 46.10 0.47 17.54 24.58 30.90 100.00 
%SD 14.15 12.63 8.26 4.72 3.28 4.84 13.09 
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Table 3.4a. MTS data obtained for IN699 cell line after 72 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 0.404 0.303 0.032 0.035 0.050 -0.020 0.388 
RUN 1  
n = 2 0.401 0.239 0.016 0.027 0.039 0.046 0.362 
RUN 1  
n = 3 0.371 0.247 0.055 0.008 0.025 0.057 0.255 
RUN 2 
n = 1 0.372 0.278 0.042 0.045 0.045 -0.060 0.369 
RUN 2 
n = 2 0.363 0.252 0.024 -0.008 0.021 0.039 0.341 
RUN 2 
n = 3 0.395 0.226 0.029 0.016 0.018 0.035 0.235 
RUN 3 
n = 1 0.374 0.297 0.075 0.046 0.067 -0.027 0.370 
RUN 3 
n = 2 0.368 0.287 0.048 0.011 0.034 0.078 0.351 
RUN 3 
n = 3 0.388 0.256 0.058 0.009 0.025 0.067 0.237 
Mean 0.382 0.265 0.042 0.021 0.036 0.024 0.323 
SD 0.015 0.027 0.019 0.018 0.016 0.048 0.062 
%Viability 118.16 82.03 13.05 6.51 11.12 7.41 100.00 
%SD 23.26 17.90 6.38 5.86 5.40 14.87 27.26 
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Table 3.4b. MTS data obtained for SC1800 cell line after 72 h. 
 Absorbance 
[DC] / 
mM 
0.01 0.1 0.25 0.5 0.75 1.0 0 
RUN 1  
n = 1 0.163 0.043 -0.115 0.009 0.016 0.034 0.065 
RUN 1  
n = 2 0.244 0.167 -0.076 0.006 0.026 0.025 0.187 
RUN 1  
n = 3 0.267 0.223 -0.015 0.024 0.068 0.032 0.243 
RUN 2 
n = 1 0.173 0.067 -0.101 0.014 0.025 0.051 0.086 
RUN 2 
n = 2 0.249 0.119 -0.057 0.022 0.044 0.036 0.155 
RUN 2 
n = 3 0.134 0.195 -0.014 0.019 0.066 0.033 0.193 
RUN 3 
n = 1 0.175 0.077 -0.106 0.012 0.032 0.058 0.100 
RUN 3 
n = 2 0.258 0.121 -0.054 0.021 0.045 0.044 0.160 
RUN 3 
n = 3 0.142 0.209 -0.010 0.030 0.071 0.036 0.203 
Mean 0.201 0.136 -0.061 0.017 0.044 0.039 0.154 
SD 0.053 0.066 0.041 0.008 0.021 0.010 0.060 
%Viability 129.86 87.72 -39.46 11.24 28.20 24.99 100.00 
%SD 60.82 54.53 -30.81 6.64 17.33 11.70 54.62 
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Table 3.5. LC50 values of DC exposed to IN699 and SC1800 cells. 
Cell line t / h LC50 / mM 
IN699 24 0.36 
48 0.19 
72 0.17 
SC1800 24 0.18 
48 0.09 
72 0.14 
 
3.3.3 Targeting glioma cells with DC 
IN699 and SC1800 cells in a 24 well plate were each treated with an aliquot of DC (either 
0.l, 0.01 or 0.001 mM) and combined bright field and fluorescence images were acquired 
using a time-lapse live cell imaging microscope (Figures 3.8 – 3.11). At all DC 
concentrations investigated, the fluorescent DC compound was observed in the IN699 
cells, but importantly, not in the SC1800 cells. These results show that DC has been very 
successfully targeted to the glioma cells, but not the non-neoplastic astrocytes and 
therefore would be a good candidate for BNCT treatments. 
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(a)    (b)    (c) 
 
(d)    (e)    (f) 
 
Figure 3.8. Combined bright field and fluorescence images of (a,b,c) glioma (IN699) cells 
and (d,e,f) astrocytes (SC1800) cells treated with DC (0.1 mM). Images acquired 3.5 h 
after incubation. Bar = 60 µm. 
The highest concentration (0.1 mM  LC50, Table 3.4) used was to ensure adequate 
fluorescence intensity could be observed, bearing in mind that the solution would be 
diluted once placed in the well containing the cells. Proof of principle was demonstrated 
using this high concentration, although image acquisition was only continued for around 6 
h: the images shown in Figures 3.8 – 3.11 were all acquired after 3.5 h; IN699 were less 
intensely stained before this time, suggesting this was the approx. time period for DC 
crossing into these cells. That IN699 cells were stained at the lowest DC concentration 
(0.001 mM), leaving the SC1800 cells unstained means successful targeting was achieved 
ca. 2 orders of magnitude below the LC50 value (ca. 0.1 mM, Table 3.4). Therefore, 
selective targeting was achieved using non-cytotoxic concentrations of DC. 
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(a)    (b)    (c) 
 
(d)    (e)    (f) 
 
Figure 3.9. Combined bright field and fluorescence images of (a,b,c) glioma (IN699) cells 
and (d,e,f) astrocytes (SC1800) cells treated with DC (0.01 mM). Images acquired 3.5 h 
after incubation. Bar = 60 µm. 
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(a)    (b)    (c) 
 
(d)    (e)    (f) 
 
Figure 3.10. Combined bright field and fluorescence images of (a,b,c) glioma (IN699) cells 
and (d,e,f) astrocytes (SC1800) cells treated with DC (0.001 mM). Images acquired 3.5 h 
after incubation. Bar = 60 µm. 
 
A control experiment was performed where IN699 and SC1800 cells were acquired using 
bright field and fluorescence imaging in the absence of DC to check that the fluorescence 
from the IN699 cells was not being produced from some auto-fluorescence phenomenon 
(Figure 3.11). As expected, no fluorescence was observed, confirming the successful 
targeting of IN699 cells with DC. 
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(a)    (b)    (c) 
 
(d)    (e)    (f) 
 
Figure 3.11. Combined bright field and fluorescence images of (a,b,c) glioma (IN699) cells 
and (d,e,f) astrocytes (SC1800) cells treated with no DC (control). Images acquired 3.5 h 
after incubation. Bar = 60 µm. 
 
3.4 Summary 
Having established that DPPC and DSPC SUV liposomes of the correct size range for 
transport across the BBB (ca. 80 – 100 nm) containing o-carborane could be successfully 
produced, the work in this chapter set about to investigate targeted delivery. The 
unselective o-carborane was successfully converted into a dequalinium salt (DC) that 
should be able to selectively target the mitrochondria of cancer cells. A high concentration 
of boron, necessary for BNCT, would thus be accumulated preferentially in cancer cells.  
In contrast to a previous study [24], DC was found to be fluorescent. Cytotoxicity of the 
compound was tested against a glioma cell line (IN699) and control non-neoplastic 
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(SC1800) cells, although LC50 values (0.36 mM and 0.18 mM for IN699 and SC1800 cells, 
respectively, for 24 h) were much greater than the concentrations of DC necessary for 
BNCT treatments. LC50 values obtained after 48 and 72 h, were of the same magnitude. 
Importantly, DC was exclusively accumulated in IN699 cells but not in SC1800 cells, 
demonstrating successful targeting. This was found over a range of DC concentrations, 
with the lower end (0.001 mM) being ca. 2 orders of magnitude below the LC50. Thus, DC 
would be an ideal non-cytotoxic boron-containing agent for use in BNCT treatment of 
cancer. 
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Chapter 4 
Spray-dried particles containing o-carborane 
4.1 Introduction 
In the previous two chapters, the aims have been to produce a stable liposome formulation 
with particles of the correct size to carry across the BBB (Chapter 2), which could contain 
a derivatised carborane to achieve cancer cell selectivity (Chapter 3). These goals have 
been met and attention is now turned to producing an alternative method of formulating 
agents for BNCT. Spray drying is a technique that produces particles from a liquid feed, 
although the particle size is usually in the 1 – 10 µm range. Such particles would be too 
large to cross the BBB, but might be useful carriers for BNCT agents to cancers other than 
brain tumours, such as those of the liver or lung. In the case of liver cancer, such 
formulations might be delivered orally or via injection since they are likely to end up in 
this organ. For lung cancer, delivery could be administered via a metred-dose inhaler 
system. These two cancer types are described before detailing the principles of spray 
drying. 
 
4.1.1 Spray drying  
Spray drying involves converting a solution or suspension into solid particles using a 
drying technique and is extensively used in the pharmaceutical and food/agricultural 
industries [1-3]. It is used as a method for microencapsulation [4,5], where fine 
particles/droplet are enveloped into efficacious larger particles [5]. Spray drying is one of a 
number of microencapsulation techniques, such as spray cooling, spray chilling, air 
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suspension coating, extrusion, centrifugal extrusion, freeze drying, rotational suspension 
separation, co-crystallisation, liposome entrapment, interfacial polymerisation and 
molecular inclusion [4,6]. Spray drying is particularly attractive as it is a one-step method 
[7] that changes a liquid feed to a dried particulate form with the ability to control particle 
size, density, morphology and solvent residue [8]. The products are usually micrometre-
sized, amorphous particles [8,9], which are often hygroscopic [7]. The physical and 
chemical properties of the feed and the instrumental conditions, such as  air flow rate, inlet 
temperature, pump speed and feed concentration [10]. 
 
The spray drier typically comprises of a feed solution, an atomiser, a gas inlet, a drying 
chamber, a cyclone and a collector [3,10]. The first process involves converting the liquid 
into a spray form via a nozzle and a compressed gas (usually air) when in contact with the 
hot chamber. The larger the drying chamber, the faster the rate of evaporation to form 
dried solid particles; these are then removed from the gas flow by means of a cyclone and 
collected. The technique involves centrifugal, kinetic and electrostatic forces [11]. 
 
The start of the drying process takes place during atomisation since the air inlet 
temperature normally is around 150 – 220 oC [12]. The air flow rate controls the residency 
time of the product in the hot drying compartment; when the residency time is increased, 
the amount of moisture removed is higher and the reduced velocity in air flow increases 
the recovery of the product (less going to exhaust) [13,14]. 
 
The drying process is also made more effective by using elevated inlet temperatures. The 
outlet temperature is usually monitored, although is not controlled operationally. Inlet 
temperature, together with pump speed (liquid flow rate), aspirator rate (rate of drying air 
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in the chamber) and concentration of the feed solution, all influence the morphology and 
size of the spray-dried particles produced. For small particles, the aspirator should be set to 
high, the inlet temperature should also be high and dilute feed solutions should be used. 
 
Spray drying allows formulations to be produced with a particle size that is ideal for drug 
delivery to the lungs. It is particularly useful for making dry powder inhaler (DPI) 
particulates [15,16]. The particle size broadly determines the locations within the airway 
the dispersed powders will be deposited [15,17]. For example, the smallest particles will 
end up in the lungs, slightly larger ones will reach the bronchioles and the largest particles 
will only travel as far as the trachea. Spray drying is useful in that it produces fairly narrow 
regions of particle size distributions, thus increasing the effectiveness of this delivery 
method. 
  
4.1.2 Polyvinylpyrolidone 
Polyvinylpyrrolidone (PVP, povidone; Figure 4.1) is a water soluble polymer that is 
effective as a drug delivery vehicle for dispersions of micro-particles [18,19]. Historically, 
PVP was used for treatment of trauma victims as a blood plasma substitute and was later 
integrated to various applications in pharmaceutics, medicine and industry [20]. PVP is 
used as an emulsifier, disintegrant and binding agent in pharmaceutics and agroculture [21-
23]. It is also a food additive: a stabiliser, E1201, as is PVPP (crospovidone), E1202. The 
polymer also enhances solubility of drugs and can help prevent recrystallisation. PVP can 
be useful in helping to disperse drugs or reagents that are poorly water soluble. PVP has 
been approved by the Food and Drug Administration (FDA) in the US [23,24], although 
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there has been a report of skin allergic reactions to PVP / povidone. An oral formulations 
of PVP was also noted to cause damage to the pulmonary vascular region when injected 
[25].  
 
N O
n
 
Figure 4.1. Structure of PVP. 
 
4.1.3 Aims 
The aim of the work in this chapter was to produce PVP / o-carborane co-spray-dried 
powders that could be used as boron-delivery vehicles for BNCT treatments via a PDI or 
similar mechanism. In this initial work, focus was resorted back to the cheaper model 
compound o-carborane, rather than using the more expensive DC compound (Chapter 3). 
PVP was used as an excipient, solubilising the o-carborane and also controlling the loading 
rate and boron content. Since spray drying produces particles in the micrometre range, the 
formulated particles would not be expected to cross the BBB. Particle diameters can be 
optimised for delivery to the lungs by controlling the spray drying parameters; this will be 
important for BNCT treatments of lung cancer. For delivery to the liver, particle size is less 
critical and the delivery mechanism would be anticipated to be the normal clearance 
mechanism. Cytotoxicity tests were also carried out. 
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4.2 Materials and methods 
4.2.1 Materials 
PVP (MW 360,000 g mol
-1
) was purchased from Sigma-Aldrich (Dorset, UK); o-carborane 
and di-sodium tetraborate (Na2B4O7.10H2O) were obtained from Alfa Aesar, UK and 
Fisher Scientific (Loughborough, UK), respectively. Distilled water (MilliQ) was used to 
prepare PVP / o-carborane solutions to be spray-dried. The cell culture reagents trypsin, 
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine Serum (FBS) and 
Penicillin-Streptomycin (PS) were obtained from Gibco. 
 
4.2.2 Methods 
4.2.2.1 Spray drying 
Aqueous solutions of PVP (1 and 2 %w/v) with and without o-carborane (0.2 %w/v) were 
prepared (100 mL, 50 mL for o-carborane containing solutions) for spray drying (Table 
4.1). Solutions were agitated (3000 rpm, electronic mini shaker) until all solids had 
dissolved (ca. 1 h) and left overnight (16 h). Spray drying was performed using a Buchi B-
290 spray drier (Buchi, Manchester, UK) using high inlet temperature (180 
o
C) and low 
inlet temperature (130 
o
C) conditions; other spray drying conditions were kept constant (air 
flow rate 52 mm, aspirator 100 %, pump speed 10 %, nozzle cleaner setting 3; Table 4.1). 
After spray drying, %recoveries were calculated and the powders stored in vials in a 
desiccator. 
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Table 4.1. Samples for spray drying and instrument inlet temperature settings. 
Sample 
number 
Product w/v% 
PVP 
w/v% o-
carborane 
Inlet temperature 
/ °C 
#1 PVP 2 0 180 
#2 PVP 2 0 180 
#3 PVP 2 0 180 
#4 PVP 2 0 180 
#5 PVP 2 0 130 
#6 PVP 2 0 130 
#7 PVP 2 0 130 
#8 PVP 1 0 180 
#9 PVP 1 0 180 
#10 PVP 1 0 180 
#11 PVP + o-carborane 2 0.2 180 
#12 PVP + o-carborane 2 0.2 180 
#13 PVP + o-carborane 2 0.2 180 
 
4.2.2.2 Particle sizing 
Particle sizing was performed on the dry powder PVP / o-carborane samples. The powders 
were dispersed using compressed air (2 bar) via the RODDOS dry powder dispenser 
(RODOS, Sympatec GmbH Germany) prior to sizing analysis with a Sympatec HELOS 
laser diffractometer (HELOS Sympatec). The particle size distribution was recorded as x10, 
x50 and x90 values using WINDOW 4.0 software (Sympatec). The values presented were the 
mean of triplicate runs. Statistical analysis was performed using IBM Statistics SPSS 
(Version 21) using a one-way ANOVA and post-hoc analysis (Tukey test).   
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4.2.2.3 NMR 
1
H, 
13
C and 
11
B NMR spectra were obtained using a JEOL Eclipse+ 400 MHz NMR 
instrument (Oxford Instruments, UK), operating at a field strength of 9.389766 T. PVP and 
o-carborane samples were dissolved in either CDCl3 or d-MeOD. 
 
4.2.2.4 SEM and EDS 
Dry powders were sprinkled onto double-sided, carbon-loaded disks attached to nickel 
SEM stubs. Excess powder was removed using a N2 stream and the samples were then 
sputter-coated with Au/Pd in an Argon atmosphere (< 0.2 Torr, 18 mA for 5 – 10 min; 
Polaron E5000 SEM coating-unit, Quorum Technologies Ltd., East Grinstead, UK). SEM 
imaging was performed immediately using a JEOL JSM-6060LV SEM instrument 
(resolution = 4.5 nm, acceleration voltage = 15 kV). EDS (Inca Oental FET×3 with high-
angle, ultra-thin window Si(Li) detector; Oxford Instruments, Oxford, UK) analysis was 
also undertaken on some of the samples investigated by SEM. A spot size of 60 and a 
working distance of 11 was used for EDS. 
 
4.2.2.5 Tissue culture and cytotoxicity studies 
Human glioblastoma U-87 MG (cancer cell line) and human fetal lung fibroblast MRC-5 
(normal cell line) cells were grown in culture at 37 
o
C in DMEM, supplemented with FBS 
(10 %v/v), penicillin (100 μg/mL), streptomycin (100 μg/mL) in a humidified atmosphere 
containing CO2 (5 %v/v). The medium was changed every 2-3 days and cells were sub-
cultured by trypsinisation before reaching ~80 % confluency in tissue culture flasks. 
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The effect of PVP / o-carborane materials (#2, #8 and #11; Table 4.1) on U-87 MG and 
MRC-5 cell proliferation capacity and viability was assessed in vitro. These samples were 
diluted in DMEM and homogenised prior to their addition in cell cultures. Briefly, cells at 
an initial density of 10
5 
cells/mL were seeded in a 24-well tissue culture plate. After 2 h 
following cell attachment to the substrate of the plate, material suspensions were added at 
various concentrations (0.1 mg/mL, 0.5 mg/mL and/or 1.0 mg/mL) before cells being 
allowed to further growth for 48 h. At this point, cells were detached by trypsinisation and 
the cell density (number of cells/mL) was determined using a Neubauer plate (cell 
counting plate). Cell proliferation was expressed as percentage (%) of cell growth 
compared to control-untreated cell cultures. Cellular death was also assessed using the 
trypan-blue dye exclusion method and reported as cell viability (% of trypan blue negative 
cells in culture). The data presented were calculated based on at least four separate 
measurements from two biological replicate experiments. 
 
4.3 Results and discussion 
4.3.1 Spray Drying 
Spray drying successfully produced white, fine powdered products of PVP / o-carborane 
(Table 4.2). Lower %yields (%recoveries) were obtained using 1 w/v% PVP than when 
using 2 w/v% PVP and consequently, co-spray-dried formulations using o-carborane were 
carried using the higher PVP concentration; similar %yields were obtained. No obvious 
changes to %yield were found when the inlet temperature from 130 to 180 °C or when co-
spray drying was employed (180 °C). 
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Table 4.2. %Yields obtained for various spray-dried formulations. 
Sample 
number 
%Yield 
#1 31.0 
#2 28.0 
#3 30.5 
#4 31.0 
#5 20.5 
#6 35.0 
#7 13.5 
#8 6.0 
#9 2.0 
#10 9.0 
#11 28.2 
#12 43.6 
#13 25.5 
 
4.3.2 
1
H NMR of PVP/o-carborane 
To check that the integrity of PVP had not been compromised during the spray drying 
process, 
1
H NMR experiments were performed. The literature spectrum was also obtained 
and used to help assign peaks (Figure 4.2) [26]. The spectra before and after spray drying 
(Figures 4.3 and 4.4), both in the absence of o-carborane, looked very similar. The signal 
corresponding to H3 appeared slightly differently in that the sharp, single peak within the 
doublet shifted slightly up field. This may be associated with hydrogen bonded water, as 
spray drying is known to produce hygroscopic, very fine amorphous powders. Peaks H1, 
H2, H4 and H5 were very similar to those in the literature [26], suggesting the PVP was 
unaffected by the spray drying process, as might be expected since there have been 
numerous reports on the spray drying of this material [27-29]. 
 
 
Chapter 4: Spray-dried particles containing o-carborane 
150 
 
Figure 4.2. Literature 
1
H NMR spectrum of PVP [26]. 
 
  
 
Figure 4.3. 
1
H NMR spectrum of ‘as received’ PVP. 
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Figure 4.4. 
1
H NMR spectrum of spray-dried PVP (2 %w/v). 
 
A 
1
H NMR spectrum of spray-dried PVP / o-carborane (Figure 4.5) was also obtained to 
see whether any peaks contained in o-carborane (Figure 4.6) were also present. Such peaks 
were not apparent in the co-spray-dried product, although this was probably due to the high 
MW of the PVP: the spectrum was simply swamped with the backbone CH2 and pendant 
pyrrolidone signals relative to the o-carborane BH and CH signals; in any case, the latter 
reagent was only present at 10 %w/v. Thus the 
1
H NMR data was inconclusive as to 
whether the o-carborane had been incorporated into the microparticles, The technique did 
establish, however, that PVP was unchanged by the spray-drying process, and particularly 
the high temperatures (180 °C) involved.      
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Figure 4.5. 
1
H NMR spectrum of PVP (2 %w/v) co-spray-dried with o-carborane (0.2 
%w/v). 
 
 
Figure 4.6. 
1
H NMR spectrum of ‘as received’ o-carborane. 
 
4.3.3 Particle sizing 
Particle diameters of spray-dried PVP and PVP / o-carborane were measured using laser 
defraction (Sympatec particle sizer). Figure 4.7 shows a typical output profile of the sizing 
results. Two plots are displayed: a particle diameter frequency plot and a cumulative 
frequency graph of particle size from which median and interquartile range data is 
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automatically generated. In the example, the mean particle diameter is ca. 3 m, although 
finer particles (‘fines’) and larger particles, the latter of which may be agglomerates, can be 
observed. To take into account the spread in size data, it is conventional to report particle 
sizes as xn values. For example, an x90 value refers to the particle diameter exhibited by 
90% of the particles; in other words, 90% of the particles will have a diameter  x. The x50 
and x10 are also often stated, which have similar definitions, and have progressively smaller 
values since less of the particles will have these particular size thresholds. The ‘bell-
shaped’ curve (’envelope’), although noting the log-scale axis, can have shoulders on 
either side of the peak maximum; shoulders on the right of the maximum almost always 
are an indication of agglomerated particles. Repeating the sizing measurement at higher 
pressures can reduce this effect, although the final delivery device operational pressure, 
e.g., in a PDI, needs to be considered. The x10, x20 and x50 particle size data are presented 
and discussed in the remainder of the this Chapter (Table 4.3a,b,c and Figure 4.8), 
although the particle size envelope data are not shown. Statistical differences between 
particle size data are shown in Tables 4.4a,b,c. 
 
 
Figure 4.7. An example Sympatec particle size distribution output plot from sample #1 run 
1 of 3 (full results in Appendix 1); x10 = 1.31 µm; x50 = 3.47 µm; x90 = 8.48 µm; 
SMD = 2.50 µm; VMD = ; x16 = 1.65 µm; x84 = 7.15 µm; x99 = 13.43 µm; SV = 2.40 m²/cm³; 
Sm = 23973.67 cm²/g. 
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The x90 data shows that mean particle diameters were ca. 2 – 10 µm, although #11 was 
17.27 ± 3.77 µm. No statistical differences (p > 0.05) were observed between different 
batches of spray-dried PVP (#1 to #4), in the absence of o-carborane, using an inlet 
temperature of 180 °C. When this temperature was decreased to 130 °C, again, no 
significant differences (p > 0.05) in x90 values were observed compared to the higher 
temperature products, although batch differences were seen between #1 and #7 (p < 0.05), 
and #2 and #7 (p < 0.05) only. Statistical differences between x90 values were also 
generally not observed (p > 0.05) when the PVP concentration was lowered to 1 %w/v. 
This temperature reduction, however, did lead to a lowering of the %yield (Section 4.3.1). 
When PVP was co-spray-dried with o-carborane, x90 values were not affected (p > 0.05), 
although for #11, x90 values were all much higher (p < 0.01 or p < 0.001) than all the other 
samples. The reason for this batch variation is uncertain, but may be due to variations in 
humidity perhaps causing agglomeration. This is examined further is Section 4.3.4.  
 
Particle sizes characterised by x50 and x10 values followed a very similar trend to the x90 
values; x10 sizes were much less than x50 and, in turn, less than x90 sizes, due to the 
definition of the xn term (Section 4.3.3). 
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Figure 4.8. Particles diameters of spray-dried particles determined using spray drying 
(mean ± SD). 
 
Table 4.3a. Statistical differences between x90 data obtained from various spray-dried 
formulations; * p < 0.05, ** p < 0.01; *** p < 0.001; NS = no significant difference. 
 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 
#1  NS NS NS NS NS * NS NS NS ** NS NS 
#2   NS NS NS NS * * NS * ** NS NS 
#3    NS NS NS NS NS NS NS *** NS NS 
#4     NS NS NS NS NS NS *** NS NS 
#5      NS NS NS NS NS *** NS NS 
#6       NS NS NS NS *** NS NS 
#7        * * NS *** NS NS 
#8         NS NS *** NS NS 
#9          NS *** NS NS 
#10           *** NS NS 
#11            *** *** 
#12             NS 
#13              
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Table 4.3b. Statistical differences between x50 data obtained from various spray-dried 
formulations; * p < 0.05, ** p < 0.01; *** p < 0.001; NS = no significant difference. 
 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 
#1  NS NS NS NS NS * NS NS NS *** NS NS 
#2   NS NS NS NS * NS NS NS *** NS NS 
#3    NS NS NS NS NS NS NS *** NS NS 
#4     NS NS NS NS NS NS *** NS NS 
#5      NS NS NS NS NS *** NS NS 
#6       NS NS NS NS *** NS NS 
#7        NS NS NS *** NS NS 
#8         NS NS *** NS NS 
#9          NS *** NS NS 
#10           *** NS NS 
#11            *** NS 
#12             *** 
#13              
  
Table 4.3c. Statistical differences between x10 data obtained from various spray-dried 
formulations; * p < 0.05, ** p < 0.01; *** p < 0.001; NS = no significant difference. 
 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 
#1  NS NS NS NS NS NS NS NS NS ** NS NS 
#2   NS NS NS NS NS NS NS NS NS NS NS 
#3    NS NS NS NS NS NS NS * NS NS 
#4     NS NS NS NS NS NS ** NS NS 
#5      NS NS NS NS NS *** NS NS 
#6       NS NS NS NS ** NS NS 
#7        NS NS NS *** NS NS 
#8         NS NS ** NS NS 
#9          NS ** NS NS 
#10           ** NS NS 
#11            ** NS 
#12             ** 
#13              
 
 
4.3.4 Morphology 
The morphology of the spray-dried powders of PVP with and without o-carborane was 
investigated using SEM. Prior to this, imaging of the ‘as received’ PVP and o-carborane 
was performed (Figure 4.9). The former consisted of large, smooth-sided crystals with 
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dimensions typically in the 100 – 500 µm range (Figure 4.9a,b). The particles of o-
carborane appeared smaller, 5 – 100 µm (Figure 4.9c,d). 
 
  
(a)      (b) 
  
(c)      (d) 
Figure 4.9. SEM images of (a,b) ‘as received’ PVP and (c,d) ‘as received’ o-carborane: 
Magnification (a) 100×, (b) 2200×, (c) 100×, (d) 800×. 
 
SEM images of spray-dried PVP, produced in the absence of o-carborane and using an 
inlet temperature of 180 °C, all showed small, rounded particles of relatively uniform size 
(< 5 µm; Figure 4.10). Dimples and hollows in the particles were observed and have been 
encountered in numerous other spray-dried products [30]: they are thought to result from 
the nozzle characteristics as the emerging droplet is formed [31]. The particle surfaces 
appeared smooth, although in some cases, smaller particles were attached, possibly being 
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due to inter-particulate forces or capillary forces causing agglomeration. No obvious 
differences in morphology were seen between different batches of spray-dried PVP 
(samples #1 to #4; Figure 4.10).  No obvious changes in morphology or particle size were 
observed when the inlet temperature was reduced to 130 °C (Figure 4.11), in agreement 
with the particle size data (Section 4.3.3). 
 
  
  
(c)      (d) 
Figure 4.10. SEM images of spray-dried PVP (inlet temperature 180 °C): Sample (a) #1, 
(b) #2, (c) #3, (d) #4; magnification 2200×. 
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(a)      (b) 
Figure 4.11. SEM images of spray-dried PVP (inlet temperature 130 °C): Sample (a) #5, 
(b) #6; magnification 2200×. 
 
SEM imaging of PVP co-spray-dried with o-carborane (Figure 4.12), in agreement with the 
particle sizing data (Section 4.3.3), generally showed similarly sized particles, although 
some particles were larger than 10 µm. In some of the SEM images of the co-spray-dried 
product, small irregularly-shaped crystalline particles were seen, which were not 
encountered in the pure spray-dried PVP products. These crystals appeared to be similar to 
those seen in the ‘as received’ o-carborane material (Figure 4.9d). It may be that the o-
carborane, which is not water-soluble, although assisted to form suspensions by the 
viscosity/swelling of the PVP, was largely unchanged by the spray drying process. A less-
magnified image of the PVP/o-carborane spray dried product revealed there to be a 
significant number of such small crystals, thought to be o-carborane (Figure 4.13); these 
were not apparent in similar images of pure spray-dried PVP (not shown). The extent of 
this phase separation is unknown. To address this situation, EDS mapping was carried out.      
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(a)      (b) 
  
(c)      (d) 
  
(e)      (f) 
Figure 4.12. SEM images of co-spray-dried PVP / o-carborane (inlet temperature 180 °C): 
Sample (a) #11, (b,c,d) #12 (different areas), (e,f) #13 (different areas); magnification 
2200×. 
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Figure 4.13. SEM images of co-spray-dried PVP/o-carborane (inlet temperature 180 °C), 
sample #13; magnification 400×. 
 
An SEM image of co-spray-dried PVP / o-carborane (sample #11) with corresponding 
EDS element maps for boron, carbon, oxygen, sodium and gold (elements giving rise to 
the highest signals) are shown in Figure 4.14. The SEM image shows the characteristic 
morphology of the spray-dried product observed previously. The assumption was that if 
the PVP was intimately mixed with o-carborane, the boron map would appear very similar 
to the SEM image. However, the boron signal (Figure 4.14b) was quite low and darker 
depressions marked regions where the particles resided, suggesting that the boron content 
was less than on the double-sided, adhesive, carbon tape. It is known that elements with 
atomic masses below carbon often not shown in EDS studies and therefore this might 
explain the absence of boron in the EDS map of the co-spray-dried particles. The carbon 
map shows an image expected from particles adhered to the carbon-loaded adhesive tape. 
Carbon atoms are also present in PVP and so the minimum brightness in the carbon map 
still remains quite high (Figure 4.14c). The oxygen map showed brighter areas where the 
particles were located, perhaps indicative of the higher oxygen atom concentration from 
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the C=O bond on the pyrrolidine ring compared with oxygen containing compounds 
associated with the carbon-loaded resin (Figure 4.14d). The sodium and gold maps did not 
reveal any significant contrast (Figure 4.14e,f).  
  
(a)      (b) B 
  
(c) C      (d) O 
  
(e) Na      (f) Au 
Figure 4.14. SEM and EDS images of co-spray-dried PVP / o-carborane sample #11: (a) 
SEM; (b) B, (c) C, (d) O, (e) Na, (f) Au. 
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To investigate whether boron-mapping was possible using this technique, a mixture of 
PVP and Na2B4O7.10H2O (1 : 1 %w/w) was ground using a mortar and pestle and 
transferred to a double-sided adhesive carbon disc on to an Al SEM stub (as in Section 
4.2.2.4) and analysed using SEM and EDS mapping (Figure 4.15). The boron map (Figure 
4.15b) again showed an inversion of the expected contrast, as observed in the boron map 
for sample #11 (Figure 4.14b). The contrast in the maps of all the other elements were as 
expected, i.e., the presence of O and Na and an absence of C on areas covered with 
particles (Na2B4O7.10H2O), and a strong Al signal for the SEM stub. To further confirm 
these observations, pure, ground Na2B4O7.10H2O crystals were similarly investigated 
(Figure 4.16). Again, similar image contrast was observed suggesting that boron-mapping 
is not effective using this technique: the atomic mass is too low. 
 
4.3.5 Cytotoxicity studies 
To check for cytotoxicity, the spray-dried powders (PVP #2 and #8, and PVP / o-carborane 
#11) were exposed to human glioblastoma U-87 MG (cancerous) and human fetal lung 
fibroblast MRC-5 (non-neoplastic) cell lines. Cell proliferation and cell death were 
determined over a range of PVP / o-carborane concentrations (0-1.0 mg/mL; Figures 4.17-
4.18). In all cases, cell proliferation did not fall below 87% and values were otherwise 
greater than 90%. Similarly, the highest cell death value was only 2.5%. No obvious 
change in cell proliferation or cell death was noted over the duration of the experiment (48 
°C Therefore, the PVP / o-carborane co-spray-dried product was described as being non-
cytotoxic at the concentrations investigated. This is in agreement with the known low 
toxicity data of the constituent PVP [32,33] and o-carborane [34] compounds. 
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(a)      (b) B 
  
(c) C      (d) O 
  
(e) Na      (f) Al 
Figure 4.15. SEM and EDS images of ‘as received’ PVP / borax mixture (1:1 wt%): (a) 
SEM; (b) B, (c) C, (d) O, (e) Na, (f) Al. 
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(a)      (b) B 
  
(c) C      (d) N 
  
(e) O      (f) Na 
Figure 4.16. SEM and EDS images of borax: (a) SEM; (b) B, (c) C, (d) N, (e) O, (f) Na. 
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Figure 4.17a. Effect of spray-dried PVP / o-carborane (samples #2, #8 and #11; combined 
results) on MRC-5 cell proliferation. 
 
Figure 4.17b. MRC-5 cell death caused by spray-dried PVP / o-carborane (samples #2, #8 
and #11; combined results). 
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Figure 4.18a. Effect of spray-dried PVP / o-carborane (samples #2, #8 and #11; combined 
results) on U87-MG cell proliferation.  
 
 
Figure 4.18b. U87-MG cell death caused by spray-dried PVP / o-carborane (samples #2, #8 
and #11; combined results). 
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4.4 Summary 
In this chapter, PVP (2 %w/v) / o-carborane (0.2 %w/v) spray-dried microparticles were 
produced with the aim providing a boron-delivery system for use in BNCT treatment of 
liver and lung cancers. Since particle sizes resulting from spray drying procedures are in 
the micrometre range, the ability of these to cross the BBB and thus BNCT treatments for 
brain tumours was not considered. 
1
H NMR studies revealed the high temperatures (180 
°C) of the spray drying process did not degrade the PVP. Mean particle diameters (x90) 
were in the 2 – 10 µm range, with finer fractions being present (x10  1 – 2 µm), and were 
therefore considered suitable for delivery to the lungs. Further optimisation of particle 
sizes could be carried out to decrease x90, for example, by changing air and liquid flow 
conditions. SEM imaging showed the particles to be spherical, with dimples and cavities 
caused by the spray drier nozzle characteristics, as typical with the spray drying process. 
Some small irregularly-shaped crystalline particles, thought to be o-carborane, were 
observed by SEM, although the proportion accounted for less that than in the formulation 
(10 %w/w). An attempt was made to map the boron content in spray-dried powders on a 
surface using EDS, although the low atomic weight of boron made detection not possible. 
Cytotoxicity studies, using human glioblastoma U-87 MG (cancerous) and human fetal 
lung fibroblast MRC-5 (non-neoplastic) cells, revealed the PVP / o-carborane co-spray-
dried particles to be non-toxic, as might have been expected. 
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Chapter 5 
Conclusions and further work 
5.1 Summary 
DPPC and DSPC SUV liposomes with particle diameters of ca. 80 – 100 nm containing o-
carborane were successfully produced using the thin film method. Those of DSPC had 
slightly larger particle sizes as reflected by their longer carbon chain. For both DPPC and 
DSPC liposomes, particle diameter increased with increasing entrapped o-carborane 
volumes. The liposomes had a monodispersed, homogeneous particle size distribution (PDI 
< 0.5), although possessed -potentials in a range indicative of instability (between -30 and 
+30 mV). However, this was probably due to high ionic strength of the PBS medium and 
re-probing was found to reduce agglomerated particle to the required size range over 
storage at 3 – 5 °C for 1 week. AFM studies showed that the loaded liposomes generally 
appeared intact after 63 days of storage if re-probing was employed. The integrity of the 
liposome membrane in serum, as reflected by %latency and %retention experiments using 
a fluorescent marker (calcein), was found to be high for both DPPC and DPPC liposomes 
prepared using cholesterol. Co-entrapment of o-carborane with Nile Red into the liposomes 
semi-quantitatively confirmed the required volume of the boron compound successfully 
became entrapped with the liposomes. This was proven quantitatively using ICP-MS 
measurements. 
  
Having established that DPPC and DSPC SUV liposomes of the correct size range for 
transport across the BBB (ca. 80 – 100 nm) containing o-carborane could be successfully 
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produced, the work in this chapter set about to investigate targeted delivery. The 
unselective o-carborane was successfully converted into a dequalinium salt (DC) that 
should be able to selectively target the mitrochondria of cancer cells. A high concentration 
of boron, necessary for BNCT, would thus be accumulated preferentially in cancer cells.  
In contrast to a previous study [1], DC was found to be fluorescent. Cytotoxicity of the 
compound was tested against a glioma cell line (IN699) and control non-neoplastic 
(SC1800) cells, although LC50 values (0.36 mM and 0.18 mM for IN699 and SC1800 cells, 
respectively, for 24 h) were much greater than the concentrations of DC necessary for 
BNCT treatments. LC50 values obtained after 48 and 72 h, were of the same magnitude. 
Importantly, DC was exclusively accumulated in IN699 cells but not in SC1800 cells, 
demonstrating successful targeting. This was found over a range of DC concentrations, 
with the lower end (0.001 mM) being ca. 2 orders of magnitude below the LC50. Thus, DC 
would be an ideal non-cytotoxic boron-containing agent for use in BNCT treatment of 
cancer. 
 
In the final chapter, PVP (2 %w/v) / o-carborane (0.2 %w/v) spray-dried microparticles 
were produced with the aim providing a boron-delivery system for use in BNCT treatment 
of liver and lung cancers. Since particle sizes resulting from spray drying procedures are in 
the micrometre range, the ability of these to cross the BBB and thus BNCT treatments for 
brain tumours was not considered. 
1
H NMR studies revealed the high temperatures (180 
°C) of the spray drying process did not degrade the PVP. Mean particle diameters (x90) 
were in the 2 – 10 µm range, with finer fractions being present (x10  1 – 2 µm), and were 
therefore considered suitable for delivery to the lungs. Further optimisation of particle 
sizes could be carried out to decrease x90, for example, by changing air and liquid flow 
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conditions. SEM imaging showed the particles to be spherical, with dimples and cavities 
caused by the spray drier nozzle characteristics, as typical with the spray drying process. 
Some small irregularly-shaped crystalline particles, thought to be o-carborane, were 
observed by SEM, although the proportion accounted for less that than in the formulation 
(10 %w/w). An attempt was made to map the boron content in spray-dried powders on a 
surface using EDS, although the low atomic weight of boron made detection not possible. 
Cytotoxicity studies, using human glioblastoma U-87 MG (cancerous) and human fetal 
lung fibroblast MRC-5 (non-neoplastic) cells, revealed the PVP / o-carborane co-spray-
dried particles to be non-toxic, as might have been expected. 
 
5.2 Further work 
This project could be continued in various directions, which are outlined below. 
  
The encapsulation of DC and the rhodamine 123 carborane salt into the DPPC and DSPC 
liposomes would be an obvious next stage since the current studies have focused on one of 
these carborane derivatised mitochondrial dyes, but not in its liposomal carrier form. It 
would also be useful to ascertain the mitochondrial membrane potentials of the cells of 
interest to check suitability or fine-tune selection of such carborane derivatised 
compounds. 
 
Spray drying of PVP containing DC and the rhodamine 123 carborane salt could also be 
carried out, since the current work used o-carborane as a model carborane material. Further 
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optimisation of the spray drying parameters might enable smaller particles to be formed, 
which would improve the ability to target the lungs. Currently, the particle size (x90) is ca. 
2 – 10 µm, although finer particles are present (x10 = 1 – 2 µm; x50 = 2 – 8 µm). ICP MS 
should be performed on the spray dried particles to determine the boron content. 
 
Another direction would be to carry out the BNCT reaction on cells that have been treated 
with the derivatised carboranes. The correct dosage would need to be optimised and cells 
could be imaged before and after the BNCT reaction to check for efficacy. Flow cytometry 
could also be used in conjunction with fluorescence imaging. Some of these studies could 
also be performed in the presence of mixed cultures of cells: cancer and non-neoplastic 
cells, or even with tissues. In vivo experiments could eventually be performed.  
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